Soleno Therapeutics (SLNO) S-1 12 Jul 16 IPO registration Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2016
Document And Entity Information [Abstract]
Document Type	S1
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Trading Symbol	CAPN
Entity Registrant Name	Capnia, Inc.
Entity Central Index Key	1,484,565
Entity Filer Category	Smaller Reporting Company

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 6,492,000	$ 5,494,523	$ 7,956,710
Accounts receivable	187,000	156,127	0
Restricted cash	35,000	35,000	20,000
Inventory	653,000	551,008	109,336
Prepaid expenses and other current assets	216,000	167,642	252,272
Total current assets	7,583,000	6,404,300	8,338,318
Long-term assets
Property and equipment, net	121,000	85,745	57,607
Goodwill	718,000	718,003	0
Other intangible assets, net	892,000	916,807	0
Other assets	76,000	76,340	0
Total assets	9,390,000	8,201,195	8,395,925
Current liabilities
Accounts payable	1,262,000	695,056	986,799
Accrued compensation and other current liabilities	1,317,000	1,632,679	201,457
Line of credit and accrued interest		0	101,529
Total current liabilities	2,579,000	3,192,735	1,289,785
Long-term liabilities
Other long-term liabilities	200,000	109,404	0
Commitments and contingencies
Stockholders' equity
Common stock	15,000	14,018	6,769
Additional paid-in-capital	95,255,000	89,456,466	59,141,405
Accumulated deficit	(89,436,000)	(86,246,673)	(70,338,127)
Total stockholders' equity	5,834,000	3,223,816	(11,189,953)
Total liabilities and stockholders' equity	9,390,000	8,201,195	8,395,925
Series A Warrant [Member]
Long-term liabilities
Warrant liability	558,000	1,212,803	857,362
Series B Warrant [Member]
Current liabilities
Warrant liability	0	865,000	0
Long-term liabilities
Warrant liability		0	17,438,731
Series C Warrant Liability [Member]
Long-term liabilities
Warrant liability	219,000	462,437
Series A Convertible Preferred Stock [Member]
Stockholders' equity
convertible preferred stock	$ 0	$ 5	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	15,403,111	14,017,909	6,769,106
Common stock, shares outstanding	15,403,111	14,017,909	6,769,106
Series A Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	40,000	40,000	40,000
Convertible preferred stock, shares issued	8,335	4,555	0
Convertible preferred stock, shares outstanding	8,335	4,555	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Product revenue	$ 447,000	$ 22,000	$ 387,555	$ 0
Government grant revenue			219,917	0
Total revenue			607,472	0
Cost of goods sold	461,000	18,000	352,683	0
Gross profit (loss)	(14,000)	4,000	254,789	0
Expenses
Research and development	1,772,000	878,000	4,536,244	2,242,216
Sales and marketing	538,000	260,000	1,737,470	252,359
General and administrative	1,939,000	1,292,000	6,140,821	2,665,154
Total expenses	4,249,000	2,430,000	12,414,535	5,159,729
Operating loss	(4,263,000)	(2,426,000)	(12,159,746)	(5,159,729)
Interest and other income (expense)
Interest income			0	1,085
Other expense	(2,000)	0	(183,565)	(7,243)
Interest expense, net	0	(1,000)	0	(4,130,394)
Change in fair value of warrants liabilities (expense)	1,170,000	(6,174,000)	(515,860)	(3,941,335)
Cease-use expense	(94,000)	0
Inducement charge for Series C warrants	0	(3,050,000)	(3,049,375)	0
Interest and other income (expense), net	1,074,000	(9,225,000)
Net loss	$ (3,189,000)	$ (11,651,000)	$ (15,908,546)	$ (13,237,616)
Basic and diluted net loss per common share (in dollars per share)	$ (0.22)	$ (1.67)	$ (1.69)	$ (10.42)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share (in shares)	14,796,119,000	6,965,483,000	9,425,880	1,270,033

Statements of Convertible Prefe

Statements of Convertible Preferred Stock and Stockholders' Equity/(Deficit) - USD ($)	Total	2010 and 2012 Convertible Promissory Notes [Member]	2014 Convertible Promissory Notes [Member]	Series A and Series B Warrants [Member]	Series A Warrant [Member]	Series B Warrant [Member]	Series B Warrant Cashless Exercises [Member]	Common Stock [Member]	Common Stock [Member]2010 and 2012 Convertible Promissory Notes [Member]	Common Stock [Member]2014 Convertible Promissory Notes [Member]	Common Stock [Member]Series A Warrant [Member]	Common Stock [Member]Series B Warrant [Member]	Common Stock [Member]Series B Warrant Cashless Exercises [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]2010 and 2012 Convertible Promissory Notes [Member]	Additional Paid-In Capital [Member]2014 Convertible Promissory Notes [Member]	Additional Paid-In Capital [Member]Series A and Series B Warrants [Member]	Additional Paid-In Capital [Member]Series A Warrant [Member]	Additional Paid-In Capital [Member]Series B Warrant [Member]	Additional Paid-In Capital [Member]Series B Warrant Cashless Exercises [Member]	Accumulated Deficit [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]
Balances at beginning at Dec. 31, 2013																						$ 1,500,000	$ 6,862,939	$ 15,445,109
Balances at beginning (shares) at Dec. 31, 2013																						31,250	119,140	715,039
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of preferred stock to common stock in IPO																						$ (1,500,000)	$ (6,862,939)	$ (15,445,109)
Conversion of preferred stock to common stock in IPO (shares)																						(31,250)	(119,140)	(715,039)
Balances at ending at Dec. 31, 2014																						$ 0	$ 0	$ 0
Balances at ending (shares) at Dec. 31, 2014																						0	0	0
Balances at beginning at Dec. 31, 2013	$ (34,195,637)							$ 522						$ 19,197,109							$ (53,393,268)
Balances at beginning (shares) at Dec. 31, 2013								522,360
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	345,435													345,435
Conversion of preferred stock to common stock in IPO	23,808,048							$ 865						23,807,183
Conversion of preferred stock to common stock in IPO, shares								865,429
Stock warrant liability reclassification	1,220,718			$ 18,975										1,220,718			$ 18,975
Issuance of common stock	9,846,552							$ 1,650						9,844,902
Issuance of common stock (shares)								1,650,000
Beneficial conversion feature in connection with related party convertible promissory notes	1,723,984													1,723,984
Conversion of notes payable into common stock in IPO		$ 15,410,110	$ 2,512,119						$ 3,166	$ 552					$ 15,406,944	$ 2,511,567
Conversion of notes payable into common stock in IPO, Shares									3,165,887	552,105
Deferred IPO costs	(1,830,450)													(1,830,450)
Warrants treated as derivative liability					$ (1,494,259)	$ (11,649,106)												$ (1,494,259)	$ (11,649,106)
Net loss	(13,237,616)																				(13,237,616)
Balance at end at Dec. 31, 2014	(11,189,953)							$ 6,769						59,141,405							(70,338,127)
Balance at end (shares) at Dec. 31, 2014								6,769,106
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series A Convertible Preferred shares(net of transaction costs of $396,343)																						$ 5
Issuance of Series A Convertible Preferred shares(net of transaction costs of $396,343) (shares)																						4,555
Balances at ending at Dec. 31, 2015																						$ 5	$ 0	$ 0
Balances at ending (shares) at Dec. 31, 2015																						4,555	0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	942,369													942,369
Issuance of common stock	293,573	$ 0			156,000	3,720,713	$ 422,540	$ 84	$ 13		$ 24	$ 619	$ 5,880	293,489	$ (13)			155,976	3,720,094	$ 416,660
Issuance of common stock (shares)								83,848	13,407		24,000	619,512	5,879,560
Contribution of Series B warrants	3,332													3,332
Derecognition of warrant liability upon exercise					$ 42,000	$ 18,853,215												$ 42,000	$ 18,853,215
Issuance of shares in conjunction with BDDI asset purchase	112,400							$ 50						112,350
Issuance of shares in conjunction with BDDI asset purchase (shares)								50,000
Issuance of shares to Aspire Capital	183,322							$ 72						183,250
Issuance of shares to Aspire Capital (shares)								71,891
Sales of shares through Aspire ATM vehicle	1,434,194							$ 507						1,433,687
Sales of shares through Aspire ATM vehicle (shares)								506,585
Issuance of Series A Convertible Preferred shares(net of transaction costs of $396,343)	4,158,657													4,158,652
Net loss	(15,908,546)																				(15,908,546)
Balance at end at Dec. 31, 2015	3,223,816							$ 14,018						$ 89,456,466							$ (86,246,673)
Balance at end (shares) at Dec. 31, 2015								14,017,909
Balances at ending (shares) at Mar. 31, 2016																						8,335
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,189,000)
Balance at end at Mar. 31, 2016	$ 5,834,000

Statements of Convertible Pref6

Statements of Convertible Preferred Stock and Stockholders' Equity/(Deficit) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Issuance of common stock in IPO, discounts & commission		$ 861,948
Series A Convertible Preferred Stock [Member]
Transaction costs	$ 396,343
Series B Warrant [Member]
Transaction costs	$ 306,116

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (3,189,000)	$ (11,651,000)	$ (15,908,546)	$ (13,237,616)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	20,000	15,000	108,228	28,516
Stock-based compensation expense	136,000	401,000	942,369	345,435
Loss on disposition of property and equipment			0	7,727
Change in fair value of common stock warrants	(1,170,000)	6,174,000	515,860	3,941,335
Non-cash interest expense relating to convertible promissory notes & amortization of discount on notes			0	4,128,863
Inducement charge for Series C warrants	0	3,050,000	3,049,375	0
Noncash expense of issuing shares to Aspire Capital			183,322	0
Change in fair value of contingent consideration	19,000	0
Non-cash interest expense relating to line of credit			0	1,529
Change in operating assets and liabilities:
Accounts receivable	(31,000)	(8,000)	(156,127)	149,605
Inventory	(102,000)	(97,000)	(441,672)	(109,336)
Other receivables			0	0
Prepaid expenses and other assets	(49,000)	(7,000)	84,630	(167,123)
Other long-term assets			(76,340)	0
Accounts payable	627,000	199,000	211,945	353,897
Accrued compensation and other current liabilities	(317,000)	115,000	1,187,626	72,806
Other long-term liabilities	72,000	0
Net cash used in operating activities	(3,984,000)	(1,809,000)	(10,299,330)	(4,484,362)
Cash flows from investing activities:
Acquisition of Neoforce assets			(1,000,000)	0
Acquisition of BDDI asset (patent)			(250,000)	0
Increase in restricted cash			(15,000)	0
Purchase of property and equipment	(19,000)	(1,000)	(55,777)	(30,683)
Net cash used in investing activities	(19,000)	(1,000)	(1,320,777)	(30,683)
Cash flows from financing activities:
Proceeds from exercise of common stock options	0	12,000	293,573	0
Proceeds from issuance of common stock to Aspire Capital			1,434,194	0
Proceeds from issuance of Series A Convertible Preferred	5,071,000	0	4,230,150	0
Repayment of credit line	0	(102,000)	(101,529)	0
Proceeds from issuance of preferred stock warrants			0	1,946
Proceeds from issuance of convertible notes payable			0	2,490,781
Proceeds from line of credit			0	100,000
Proceeds from Initial Public Offering			0	10,727,475
Initial Public Offering costs paid	0	(530,000)	(575,181)	(2,117,217)
Net cash provided by financing activities	5,000,000	3,382,000	9,157,920	11,202,985
Net increase (decrease) in cash and cash equivalents	997,000	1,572,000	(2,462,187)	6,687,940
Cash and cash equivalents, beginning of period	5,494,523	7,956,710	7,956,710	1,268,770
Cash and cash equivalents, end of period	6,492,000	9,529,000	5,494,523	7,956,710
Supplemental disclosures of noncash investing and financing information
Series A preferred convertible stock transaction costs included in Accounts Payable			71,493	0
Shares issued	1,665,000	0	112,400	0
Reduction in initial public offering costs payable	0	45,000
Fixed asset costs included in accounts payable	11,000	0
Series B Warrant transaction costs accrued and included in	0	131,000
BDDI patent purchase consideration included in accrued liabilities			200,000	0
Cashless exercise of 2010 and 2012 warrants			13	0
Contribution of Series B warrants			3,332	0
Initial Public Offering costs accrued and included in Accounts Payable			0	575,181
Beneficial conversion feature related to the warrants to purchase shares of convertible preferred stock in connection with convertible promissory notes			0	1,723,984
Issuance of warrants for the purchase of convertible preferred stock in connection with notes payable			0	966,978
Series A Warrant [Member]
Cash flows from financing activities:
Gross proceeds upon exercise of warrants	0	156,000	156,000	0
Series A Warrant [Member] | Cash Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition of warrant liability	0	42,000	42,000	0
Series B Warrant [Member]
Cash flows from financing activities:
Series B warrant transaction costs paid	0	(175,000)
Gross proceeds upon exercise of warrants			3,720,713	0
Series B Warrant [Member] | Cash Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition of warrant liability	0	6,748,000	6,747,765	0
Series B Warrant [Member] | Cashless Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition of warrant liability	593,000	417,000	12,527,991	0
Private Placement Series B Warrants [Member]
Cash flows from financing activities:
Gross proceeds upon exercise of warrants	0	3,832,000
Tender Offer Series B Warrants [Member]
Cash flows from financing activities:
Gross proceeds upon exercise of warrants	0	189,000
Series A Convertible Preferred Stock [Member]
Cash flows from financing activities:
Initial Public Offering costs paid	$ (71,000)	$ 0
IPO [Member] | 2014 Convertible Promissory Notes [Member]
Supplemental disclosures of noncash investing and financing information
Notes payable converted into common stock in IPO			0	2,512,119
IPO [Member] | 2010 and 2012 Convertible Promissory Notes [Member]
Supplemental disclosures of noncash investing and financing information
Notes payable converted into common stock in IPO			$ 0	$ 15,410,110

Description of Business

Description of Business	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Capnia, Inc. (the “Company”) was incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. The Company develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. On September 8, 2015, the Company established NeoForce, Inc. (“NeoForce”), a wholly owned subsidiary of the Company and acquired substantially all of the assets of an unrelated privately held company NeoForce Group, Inc.(“NFG”). NeoForce develops innovative pulmonary resuscitation solutions for the inpatient and ambulatory neonatal markets. On April 27, 2015, the Company established Capnia UK Limited, a wholly owned foreign subsidiary in the United Kingdom. Capnia UK Limited began sales and marketing operations in the first quarter of 2016. The Company’s first diagnostic product, CoSense ®	Note 1. Description of Business Capnia, Inc. (the “Company”) was incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. The Company develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. On September 2, 2015, the Company established NeoForce, Inc. (“NFI”), a wholly owned subsidiary incorporated in the State of Delaware. On September 8, 2015, NFI, acquired substantially all of the assets of an unrelated privately held company NeoForce Group, Inc. (“NeoForce”) in exchange for an upfront cash payment of $1.0 million and royalties on future sales (see Note 15). NeoForce developed innovative pulmonary resuscitation solutions for the inpatient and ambulatory neonatal markets that the Company is now marketing through NFI. On April 27, 2015, the Company established Capnia UK Limited, a wholly owned foreign subsidiary in the United Kingdom. There have been no significant activities for this entity to date. The Company’s first diagnostic product, CoSense ®

Liquidity, Financial Condition

Liquidity, Financial Condition and Management's Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Financial Condition and Management's Plans	Note 2. Liquidity, Financial Condition and Management’s Plans The Company had a net loss of $3.2 million for the three months ended March 31, 2016 and has an accumulated deficit of approximately $89.4 million at March 31, 2016 from having incurred losses since its inception. The Company has approximately $5.0 million of working capital at March 31, 2016 and used $4.0 million of cash in its operating activities during the three months ended March 31, 2016. The Company has financed its operations principally through issuances of debt and equity securities. On July 24, 2015, the Company entered into a Common Stock Purchase Agreement (the “Aspire Purchase Agreement”) with Aspire Capital, LLC (“Aspire”) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire is committed to purchase up to an aggregate of $10.0 million in value of shares of the Company’s Common Stock over the 24-month term of the Aspire Purchase Agreement. As of April 4, 2016, the restrictions on the use of the Aspire Purchase Agreement imposed by the Sabby Purchase Agreement expired. On October 12, 2015, the Company entered into a Securities Purchase Agreement (the “Sabby Purchase Agreement”) with funds managed by Sabby Management, LLC (“Sabby”), to purchase up to $10 million worth of Series A Convertible Preferred Stock (the “Series A Preferred Stock”). The sale of the Series A Preferred Stock closed in two separate closings. On October 15, 2015, the date of the first closing, the Company received proceeds of approximately $4.1 million, net of $0.4 million in estimated expenses. Upon the second closing on January 8, 2016, the Company received proceeds of approximately $5.0 million, net of $0.5 million in estimated expenses. The Company expects to continue incurring losses for the foreseeable future and may be required to raise additional capital to pursue its product development initiatives and penetrate markets for the sale of its products. Management believes that the Company’s commercial products, including CoSense, the other neonatology products and Serenz, and the distribution strategies implemented will begin to generate meaningful revenue and corresponding cash in the near term. In addition, the Company has been successful over the last 12 months in raising additional capital, including closing pursuant to the Aspire Purchase Agreement and most recently in January of 2016 with the second closing pursuant to the Sabby Purchase Agreement. Management believes that the Company has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company has not secured any commitment for new financing at this time nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its development of new products and take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company.	Note 2. Liquidity, Financial Condition and Management’s Plans The Company had a net loss of $15.9 million for the year ended December 31, 2015 and has an accumulated deficit of approximately $86.2 million at December 31, 2015 from having incurred losses since its inception. The Company has approximately $3.2 million of working capital at December 31, 2015 ($4.1 million of working capital when excluding the Series B warrant liability) and used approximately $10.3 million of cash in its operating activities during the year ended December 31, 2015. The Company has financed its operations principally through issuances of debt and equity securities. The Company completed its initial public offering (“IPO”) on November 18, 2014 upon the issuance of 1,650,000 units, each of which consisted of one share of Common Stock, one Series A Warrant and one Series B Warrant, at an offering price of $6.50 per unit and received net proceeds of $8.0 million, after deducting underwriting discounts and commissions and IPO related expenses. The Series A Warrants are registered securities that are freely tradable on the NASDAQ. The Series B Warrants have variable settlement provisions (see Note 6). On March 5, 2015 the Company received approximately $3.8 million as a result of Series B Warrant holders exercising warrants to purchase shares of the Company’s Common Stock (the “Private Transaction”). In addition, on March 6, 2015 the Company received approximately $0.2 million as a result of Series A Warrant holders exercising warrants to purchase shares of the Company’s Common Stock. During the year ended December 31, 2015 the Company received $0.3 million from the exercise of stock options. On July 24, 2015, the Company entered into a Common Stock purchase agreement with Aspire Capital Fund, LLC, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million in value of shares of the Company’s Common Stock over the 24-month term of the Aspire Purchase Agreement (as defined below). During the quarter ended September 30, 2015, the Company issued an aggregate of 506,585 shares of Common Stock to Aspire Capital in exchange for approximately $1.4 million. On October 12, 2015, the Company entered into a Securities Purchase Agreement (the “Sabby Purchase Agreement”) with funds managed by Sabby Management, LLC (“Sabby”), to purchase up to $10 million worth of Series A Convertible Preferred Stock (the “Preferred Stock”). The sale of the Preferred Stock was set to take place in two separate closings. On October 15, 2015, the date of the first closing, the Company received proceeds of approximately $4.1 million, net of $0.4 million in estimated expenses. Upon the second closing, which closed on January 8, 2016, the Company received proceeds of approximately $5.0 million, net of $0.5 million in estimated expenses (see Note 15). The Company may generate future revenue from a variety of sources, including sales of its neonatology products, other diagnostic products, license fees, milestone payments, and research and development payments in connection with potential future strategic partnerships. However, to date, the Company has generated minimal revenue. The Company may never generate revenue that is sufficient to be profitable in the future. If the Company does not generate significant revenue, it may have to raise capital through additional equity or debt financing. The Company’s failure to achieve sustained profitability could depress the value of the Company and could impair the ability to raise capital. Management believes that the Company has sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies during the three months ended March 31, 2016, as compared to the significant accounting policies described in Note 3 of the “Notes to Consolidated Financial Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Below are those policies with current period updates: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the Company’s financial position as of March 31, 2016 and results of its operations and cash flows for the three months ended March 31, 2016 and 2015. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. Certain prior period amounts have been reclassified to conform to current period presentation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, liability and equity instruments, stock-based compensation, acquired intangibles, contingent earn-out consideration, and allowances for accounts receivable and inventory. Inventory As of December 31, 2015 and March 31, 2016, the Company’s inventory was comprised of the following (in thousands): March 31, December 31, Raw materials $ 290 $ 106 Work-in-process 267 399 Finished goods 96 46 Total inventory $ 653 $ 551 Inventory is stated at the lower of cost or market under the first-in, first-out (FIFO) method. Intangible Assets Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 5 to 12 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life. Goodwill The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. There was no impairment of goodwill for the three months ended March 31, 2016. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies Common Stock purchase warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company determined that certain freestanding derivatives, which principally consist of Series A, Series B, and Series C Warrants to purchase Common Stock, do not satisfy the criteria for classification as equity instruments due to the existence of certain cash settlement features that are not within the sole control of the Company or variable settlement provision that cause them to not be indexed to the Company’s own stock. Due to certain provisions contained in the Series B Warrant agreement that provides for the Company potentially issuing an unlimited number of shares upon exercise, the Company had adopted a sequencing policy that reclassified contracts, with the exception of stock options, from equity to assets or liabilities for those with the latest inception date first. The Company had evaluated the issuance of securities as to reclassification as a liability under this sequencing policy through February 12, 2016, the date that the Series B Warrants expired. Recent Accounting Pronouncements There have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended March 31, 2016 as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 that are of significance or potential significance to the Company.	Note 3. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Principles of Consolidation The consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of liabilities and equity instruments, stock-based compensation, value and life of acquired intangibles, and allowances for accounts receivable and inventory. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at two commercial banks that management believes are of high credit quality. Cash and cash equivalents deposited with these commercial banks exceeded the Federal Deposit Insurance Corporation insurable limit at December 31, 2015 and December 31, 2014. The Company expects this to continue. Segments The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting, making operating decisions, and assessing financial performance. All long-lived assets are maintained in the United States of America. Cash and Cash Equivalents The Company considers all highly liquid investments, including its money market fund, purchased with an original maturity of three months or less to be cash equivalents. The Company’s cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market fund which was unrestricted as to withdrawal or use. Accounts Receivable Accounts receivable as of December 31, 2015 consist of balances due from customers in the normal course of business. The Company did not record an allowance for doubtful accounts as this balance was deemed fully collectible. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of payments primarily related to insurance and short-term deposits. Prepaid expenses are initially recorded upon payment and are expensed as goods or services are received. Inventory Inventory as of December 31, 2014 consisted of raw materials to be used in the manufacture of our products. As of December 31, 2015, the Company’s inventory includes approximately $106,000 of raw material, $398,000 of work-in-process and $46,000 of finished goods. Inventory is stated at the lower of cost or market under the first-in, first-out (FIFO) method. Patent On June 30, 2015, the Company entered into an amendment of the BDDI Asset Purchase Agreement (the “BDDI Amending Agreement”), under which the Company committed to pay aggregate cash payments of $450,000 and issued 40,000 shares of Common Stock to an affiliate of BDDI. With respect to the aggregate cash payments of $450,000, the Company paid an affiliate of BDDI an initial sum of $150,000 on July 1, 2015, and is obligated to pay $100,000 on each of the six, twelve and eighteen-month anniversaries of the signing of the amended agreement. The Company made the first installment of $100,000 on December 21, 2015. The remaining $200,000 payable under this agreement has been included in Accrued compensation and other current liabilities on the balance sheet. Under the original Asset Purchase Agreement dated June 11, 2010, the Company purchased a patent for Breath End Tidal Gas Monitor. The patent was issued on June 19, 2003 and expires on August 1, 2027. The Company has capitalized the fair value of the patent purchased as an intangible asset on its consolidated balance sheet, and is amortizing the fair value over the remaining useful life of the patent. In July 2015, the Company also entered into a consulting agreement with an affiliate of BDDI. As part of this consulting agreement the Company issued 10,000 shares to the affiliate of BDDI. Business Combinations For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations. Property and Equipment, Net Property and equipment are stated at cost net of accumulated depreciation and amortization calculated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value. Intangible Assets Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 5 to 12 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life. Intangible assets consist of the following at December 31, 2015: Amount Accumulated Net Amount Useful Lives Patents and trademarks $ 697,890 $ (32,155 ) $ 665,735 5-12 Customer contracts 259,730 (8,658 ) 251,072 10.00 Total $ 957,620 $ (40,813 ) $ 916,807 Future amortization expense for intangible assets over their remaining useful lives is as follows: Year ending December 31: Patents and Customer contracts Total Amortization 2016 $ 73,370 $ 25,973 $ 99,343 2017 73,370 25,973 99,343 2018 73,370 25,973 99,343 2019 73,370 25,973 99,343 2020 and thereafter 372,255 147,180 519,435 Total $ 665,735 $ 251,072 $ 916,807 Goodwill The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. There was no impairment of goodwill for the year ended December 31, 2015. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. Revenue Recognition The Company began recognizing sales of CoSense during the year ended December 31, 2015. In addition, the Company began recognizing sales of NFI pulmonary resuscitation products after the acquisition of Neoforce’s assets in September 2015. The Company recognizes revenue when all of the following criteria are met: • persuasive evidence of an arrangement exists; • the sales price is fixed or determinable; • collection of the relevant receivable is probable at the time of sale; and • delivery has occurred or services have been rendered. For a majority of sales, where the Company delivers its product to hospitals or medical facilities, the Company recognizes revenue upon delivery, which represents satisfaction of the required revenue recognition criteria. The Company does not offer rights of return or price protection and it has no post-delivery obligations. The Company offers a limited one-year warranty to most customers. Estimated warranty obligations are recorded at the time of sale and to date, warranty costs have been insignificant. The Company also recognized revenue related to a government grant awarded during the year ended December 31, 2015. Government grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. Revenue related to government grants is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable performance obligations under the government grants have been met. Funds received under government grants are recorded as revenue if the Company is deemed to be the principal participant in the contract arrangements because the activities under the contracts are part of the Company’s development programs. If the Company is not the principal participant, the funds from government grants are recorded as a reduction to research and development expense. Funds received from government grants are not refundable and are recognized when the related qualified research and development expenses are incurred and when there is reasonable assurance that the funds will be received. Research and Development Research and development costs are charged to operations as incurred. Research and development costs consist primarily of salaries and benefits, consultant fees, prototype expenses, certain facility costs and other costs associated with clinical trials, net of reimbursed amounts. Research and development costs include costs of $220,000 incurred and reimbursed under the government grant awarded in the year ended December 31, 2015. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the amounts at which assets and liabilities are recorded for financial reporting purposes and the amounts recorded for income tax purposes. Deferred income taxes are classified as current or non-current, based on the classifications of the related assets and liabilities giving rise to the temporary differences. A valuation allowance is provided against the Company’s deferred income tax assets when their realization is not reasonably assured. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. Convertible Preferred Stock and other Hybrid Instruments The Company’s convertible preferred stock was classified as permanent equity on its balance sheet in accordance with authoritative guidance for the classification and measurement of hybrid securities and distinguishing liability from equity instruments. The preferred stock is not redeemable at the option of the holder. Further, the Company evaluated its Series A Convertible Preferred Stock and determined that it is considered an equity host under ASC 815, Derivatives and Hedging Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies Common Stock purchase warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company determined that certain freestanding derivatives, which principally consist of Series A, Series B, and Series C warrants to purchase Common Stock, do not satisfy the criteria for classification as equity instruments due to the existence of certain cash settlement features that are not within the sole control of the Company or variable settlement provision that cause them to not be indexed to the Company’s own stock. The Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the latest inception date first. Future issuance of securities will be evaluated as to reclassification as a liability under our sequencing policy of latest inception date first until either all of the Series B warrants are settled or expire. Stock-Based Compensation For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the estimated fair value on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model, as they are earned. The awards generally vest over the time period the Company expects to receive services from the non-employee. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. In April 2015, the Financial Accounting Standards Board (FASB) issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU No. 2016-02, Leases. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4. Fair Value of Financial Instruments The carrying value of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to the short-term nature of these items. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: • Level I Unadjusted quoted prices in active markets for identical assets or liabilities; • Level II Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and • Level III Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements at March 31, 2016 Total Level 1 Level 2 Level 3 Assets Money market fund $ 3,975 $ 3,975 $ — $ — Liabilities Series A warrant liability $ 558 $ 558 $ — $ — Series C warrant liability 219 — — 219 Total liabilities $ 777 $ 558 $ — $ 219 Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets Money market fund $ 3,804 $ 3,804 $ — $ — Liabilities Series A warrant liability $ 1,213 $ 1,213 $ — $ — Series B warrant liability 865 — — 865 Series C warrant liability 462 — — 462 Total common stock warrant liability $ 2,540 $ 1,213 $ — $ 1,327 The Series A Warrant is a registered security that trades on the open market. The fair value of the Series A Warrant liability is based on the publicly quoted trading price of the warrants which is listed on and obtained from NASDAQ. Accordingly, the fair value of Series A Warrants is a Level 1 measurement. The fair value measurements of the Series B and Series C Warrants are based on significant inputs that are unobservable and thus represent Level 3 measurements. The Company’s estimated fair value of the Series B Warrant liability is calculated using a Monte Carlo simulation. Key assumptions include the volatility of the Company’s stock, the expected warrant term, expected dividend yield and risk-free interest rates (see Note 5). The Company’s estimated fair value of the Series C Warrant liability is calculated using the Black-Scholes valuation model. Key assumptions include the volatility of the Company’s stock, the expected warrant term, expected dividend yield and risk-free interest rates (see Note 5). The Level 3 estimates are based, in part, on subjective assumptions. The agreement to pay the annual royalty in the NFG acquisition resulted in the recognition of a contingent consideration, which was recognized at the inception of the acquisition. Subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. Based on the assumptions, the fair value of the royalty was determined to be $153 thousand at the date of acquisition and $172 thousand as of March 31, 2016. The fair value of the royalty was determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate of 20% commensurate with the Company’s cost of capital and expectation of the revenue growth for products at their life cycle stage. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. On January 13, 2016 we entered into an agreement to sublease our excess space located in Redwood City. By the end of February we removed all equipment, furniture and fixtures being stored in this excess space and ceased use of this space. The fair value of the cease-use liability was calculated using the remaining lease payments, offset by future sub-lease payments, offset by deferred rent amortization, and discounted to present value using our current cost of capital of 20%. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the periods presented. The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 and Level 3 warrants, which are treated as liabilities, as follows (dollars in thousands): Series A Warrant Series B Warrant Series C Warrant Number of Liability Number of Liability Number of Liability Balance at December 31, 2015 2,425,605 $ 1,213 116,580 $ 865 590,415 $ 462 Change in value of Series A Warrants — (655 ) — — — — De-recognition of Series B Warrant liability upon cashless exercise of warrants (485,202 shares issued) — — (102,300 ) (593 ) — — De-recognition of Series B Warrant liability upon expiration — — (14,280 ) — — — Change in value of Series B Warrants — — — (272 ) — — Change in value of Series C Warrants — — — — — (243 ) Balance at March 31, 2016 2,425,605 $ 558 — $ — 590,415 $ 219	Note 4. Fair Value of Financial Instruments The carrying value of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to the short-term nature of these items. Based on the borrowing rates available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the line of credit approximates fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: • Level I Unadjusted quoted prices in active markets for identical assets or liabilities; • Level II Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and • Level III Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets Money market fund $ 3,803,929 $ 3,803,929 — — Liabilities Series A warrant liability 1,212,803 1,212,803 — — Series B warrant liability 865,000 — — 865,000 Series C warrant liability 462,437 — — 462,437 Total common stock warrant liability $ 2,540,240 $ 1,212,803 — $ 1,327,437 Fair Value Measurements at December 31, 2014 Total Level 1 Level 2 Level 3 Assets Money market fund $ 7,891,888 $ 7,891,888 $ — $ — Liabilities Series A warrant liability 857,362 857,362 — — Series B warrant liability 17,438,731 — — 17,438,731 Total common stock warrant liability $ 18,296,093 $ 857,362 — $ 17,438,731 The Series A Warrant is a registered security that trades on the open market. The fair value of the Series A Warrant liability is based on the publicly quoted trading price of the warrants which is listed on and obtained from NASDAQ. Accordingly, the fair value of Series A Warrants is a Level 1 measurement. The fair value measurements of the Series B and Series C Warrants are based on significant inputs that are unobservable and thus represent Level 3 measurements. The Company’s estimated fair value of the Series B Warrant liability is calculated using a Monte Carlo simulation. Key assumptions include the volatility of the Company’s stock, the expected warrant term, expected dividend yield and risk-free interest rates (see Note 6). The Company’s estimated fair value of the Series C Warrant liability is calculated using the Black-Scholes valuation model. Key assumptions include the volatility of the Company’s stock, the expected warrant term, expected dividend yield and risk-free interest rates (see Note 6). The Level 3 estimates are based, in part, on subjective assumptions. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the periods presented. The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 and Level 3 financial instruments, which are treated as liabilities, as follows: Series A Warrant Series B Warrant Series C Warrant Number of Liability Number of Liability Number of Liability Balance at December 31, 2014 2,449,605 $ 857,362 2,449,605 $ 17,438,731 — $ — Change in value of Series A Warrants — 397,441 — — — — De-recognition of Series A Warrant liability upon exercise (24,000 ) (42,000 ) — — — — De-recognition of Series B Warrant liability upon cash exercise of 619,512 warrants in Private Transaction (619,512 shares issued) — — (619,512 ) (6,747,765 ) — — De-recognition of Series B Warrant liability upon cashless exercise of 1,713,045 warrants (5,879,560 shares issued) — — (1,713,045 ) (12,527,991 ) — — De-recognition of Series B Warrant liability upon contribution of 468 warrants back to the Company — — (468 ) (3,332 ) — — Change in value of Series B Warrants — — — 2,705,357 — — Record Series C Warrant Liability as inducement charge (589,510 warrants in Private Transaction, 905 warrants in tender offer) — — — — 590,415 3,049,375 Change in value of Series C Warrants — — — — — (2,586,938 ) Balance at December 31, 2015 2,425,605 $ 1,212,803 116,580 $ 865,000 590,415 $ 462,437

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 5. Property and Equipment, Net Property and equipment consisted of the following: December 31, December 31, Furniture and fixtures $ 236,366 $ 180,238 Computer hardware 52,112 27,555 Leasehold improvements 9,117 10,726 $ 297,595 $ 218,519 Less accumulated depreciation and amortization (211,850 ) (160,912 ) Total $ 85,745 $ 57,607 Depreciation expense was $67,415 and $28,516 for the fiscal years ended December 31, 2015 and December 31, 2014, respectively.

Warrant Liabilities

Warrant Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Text Block [Abstract]
Warrant Liabilities	Note 5. Warrant Liabilities Warrants terms The Company has issued Series A Warrants, Series B Warrants and Series C Warrants (the “Warrants”). The Company’s Warrants contain standard anti-dilution provisions for stock dividends, stock splits, subdivisions, combinations and similar types of recapitalization events. They also contain a cashless exercise feature that provides for their net share settlement at the option of the holder in the event that there is no effective registration statement covering the continuous offer and sale of the warrants and underlying shares. The Company is required to comply with certain requirement to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Warrant contracts further provide for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration statement as described herein. The Company evaluated the registration payment arrangement stipulated in the terms of these securities and determined that it is probable that the Company will maintain an effective registration statement and has therefore not allocated any portion of the Company’s cash or cash equivalents to the registration payment arrangement. The Warrants also contain a fundamental transactions provision that permits their settlement in cash at fair value at the option of the holder upon the occurrence of a change in control. Such change in control events include tender offers or hostile takeovers, which are not within the sole control of the Company as the issuer of these Warrants. Accordingly, the Warrants are considered to have a cash settlement feature that precludes their classification as equity instruments. Settlement at fair value upon the occurrence of a fundamental transaction would be computed using the Black Scholes Option Pricing Model. Accounting Treatment The Company accounts for the Warrants in accordance with the guidance in ASC 815 Derivatives and Hedging The Company classified the Warrants as liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as other income (expense) in the Company’s statement of operations. Under ASC 815-40-35, the Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the latest inception date first. Future issuance of securities will be evaluated as to reclassification as a liability under our sequencing policy of latest inception date first until either all of the Series B Warrants are settled or expire. The Series B Warrants expired on February 12, 2016. In accordance with the guidance under ASC 815-40-25, we have evaluated that we have a sufficient number of authorized and unissued shares as March 31, 2016, to settle all existing commitments. Series A Warrants The Company has issued 2,449,605 Series A Warrants to purchase shares of its Common Stock at an exercise price of $6.50 per share in connection with the unit offering offered in the Company’s initial public offering (“IPO”) described in Note 2. The Series A Warrants are exercisable at any time prior to the expiration of the five-year term on November 12, 2019. Upon the completion of the IPO, the Series A Warrants started trading on the NASDAQ under the symbol CAPNW. As the Series A Warrants are publicly traded, the Company uses the closing price on the measurement date to determine the fair value of these the Series A Warrants. Since their issuance, a total of 24,000 Series A Warrants have been exercised. As of March 31, 2016, the fair value of the 2,425,605 outstanding Series A Warrants was approximately $558 thousand, and the decrease of $655 thousand in fair value during the three months ended March 31, 2016 was recorded as other income in the statement of operations. Series B Warrants The Company issued 2,449,605 Series B Warrants to purchase shares of its Common Stock at an exercise price of $6.50 per share in connection with the Initial Public Offering. The unexercised Series B Warrants expired on February 12, 2016. The net decrease in carrying amount of the Series B Warrants for the three months ended March 31, 2016 was $865 thousand, of which $271 thousand was attributed to the change in fair value of the warrant liability during the three months ended March 31, 2016 and was recorded as other expense in the consolidated statement of operations. Factors contributing to the change in fair value of the Series B Warrants include the trading price of the Common Stock and term remaining to expiration of the Series B Warrants. Before the expiration date of February 12, 2016, certain holders of Series B warrants cashless exercised a total of 102,300 warrants resulting in the issuance of 485,202 shares of Common Stock and the derecognition of approximately $594 thousand, in Series B Warrant liability, respectively for the three months ended March 31, 2016, which was recorded as additional paid-in capital. Series C Warrants On March 5, 2015, the Company entered into separate agreements with certain Series B Warrant holders, who agreed to exercise their Series B Warrants to purchase an aggregate of 589,510 shares of the Company’s Common Stock at an exercise price of $6.50 per share, resulting in the de-recognition of $6.7 million of Series B Warrant liability and gross proceeds to the Company of approximately $3.8 million based on the exercise price of the Series B Warrants. In connection with this exercise of the Series B Warrants, the Company issued to each investor who exercised Series B Warrants, new Series C Warrants for the number of shares of the Company’s Common Stock underlying the Series B Warrants that were exercised. Each Series C Warrant is exercisable at $6.25 per share and will expire on March 5, 2020. In April 2015, the Company issued a tender offer to the remaining holders of Series B Warrants to induce the holders to cash exercise the outstanding Series B Warrants in exchange for new Series C Warrants with an exercise price of $6.25 per share that expire on March 5, 2020. The tender offer was extended to warrant holders under a registration statement filed with the SEC on Form S-4, which was declared effective on June 25, 2015 and expired on July 24, 2015. During July 2015, certain Series B Warrant holder(s) tendered their Series B Warrants under the tender offer, which resulted in the issuance of 905 shares of Capnia Common Stock, the issuance of 905 Series C Warrants and proceeds to the Company of $5,882. The new Series C Warrants are exercisable into 590,415 shares of the Company’s Common Stock. As of March 31, 2016, the fair value of the Series C Warrants was determined to be $219 thousand. The decline in the fair value of the Series C Warrants of $244 thousand in the three months ended March 31, 2016 was recorded as other income in the consolidated statement of operations. The Company has calculated the fair value of the Series C Warrants using a Black-Scholes pricing model, which requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs: March 31, December 31, Volatility 90 % 90 % Expected Term (years) 3.92 4.17 Expected dividend yield — % — % Risk-free rate 1.03 % 1.76 %	Note 6. Warrant Liabilities Warrants terms The Company has issued Series A Warrants, Series B Warrants and Series C Warrants (the “Warrants”). The Company’s Series A, Series B and Series C Warrants contain standard anti-dilution provisions for stock dividends, stock splits, subdivisions, combinations and similar types of recapitalization events. They also contain a cashless exercise feature that provides for their net share settlement at the option of the holder in the event that there is no effective registration statement covering the continuous offer and sale of the warrants and underlying shares. The Company is required to comply with certain requirement to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Warrant contracts further provide for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration statement as described herein. The Company evaluated the registration payment arrangement stipulated in the terms of these securities and determined that it is probable that the Company will maintain an effective registration statement and has therefore not allocated any portion of the IPO or Private Transaction proceeds to the registration payment arrangement. The Warrants also contain a fundamental transactions provision that permits their settlement in cash at fair value at the option of the holder upon the occurrence of a change in control. Such change in control events include tender offers or hostile takeovers, which are not within the sole control of the Company as the issuer of these warrants. Accordingly, the warrants are considered to have a cash settlement feature that precludes their classification as equity instruments. Settlement at fair value upon the occurrence of a fundamental transaction would be computed using the Black Scholes Option Pricing Model. Accounting Treatment The Company accounts for the Warrants in accordance with the guidance in ASC 815 Derivatives and Hedging Additionally, the terms of the Series B Warrants do not explicitly limit the potential number of shares, thereby the exercise of the Series B Warrants could result in the Company’s obligation to deliver a potentially unlimited number of shares upon settlement. As such, share settlement is not considered to be within the control of the Company. The Company classified the Series A, Series B, and C Warrants as liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as other income (expense) in the Company’s statement of operations. Under ASC 815-40-35, the Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the latest inception date first. Future issuance of securities will be evaluated as to reclassification as a liability under our sequencing policy of latest inception date first until either all of the Series B warrants are settled or expire. (see Note 15) In accordance with the guidance under ASC 815-40-25, we have evaluated that we have a sufficient number of authorized and unissued shares as December 31, 2015, to settle all existing commitments. Series A Warrants The Company has issued 2,449,605 Series A Warrants to purchase shares of its Common Stock at an exercise price of $6.50 per share in connection with the IPO unit offering described in Note 2. The Series A Warrants are exercisable at any time prior to the expiration of the five-year term on November 12, 2019. Upon the completion of the IPO, the Series A warrants started trading on the NASDAQ under the symbol CAPNW. As the warrants are publicly traded, the Company uses the closing price on the measurement date to determine the fair value of these warrants. During the year ended December 31, 2015, a total of 24,000 Series A Warrants were exercised. As of December 31, 2015, the fair value of the 2,425,605 outstanding Series A warrants was approximately $1.2 million, and the increase of $0.4 million in fair value during the year ended December 31, 2015 was recorded as other expense in the statement of operations. Series B Warrants The Company has issued 2,449,605 Series B Warrants to purchase shares of its Common Stock at an exercise price of $6.50 per share in connection with the IPO unit described in Note 2. The Series B Warrants are exercisable at any time prior to the expiration of the 15-month term on February 12, 2016. In the event that the market price of the Company’s Common Stock falls below $6.50 at any time between March 12, 2015 and February 12, 2016 (expiration date), the Series B Warrants will become exercisable on a cashless basis for a number of common shares that increases as the market price of the Company’s Common Stock decreases, and exercisable at a discount to the tracking price of the Common Stock at the time. The result is an inverse relationship between the fair value of the shares and the number of shares issuable upon exercise. As of December 31, 2015 and December 31, 2014 the Company used a Monte Carlo simulation to calculate the fair value of its Series B Warrant liability. This model is dependent upon several variables such as the warrant’s term, exercise price, current stock price, risk-free interest rate estimated over the contractual term, estimated volatility of our stock over the term of the warrant and the estimated market price of our stock during the cashless exercise period. The risk-free rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending the volatility rates for a number of similar publicly-traded companies. The Company used the following inputs: December 31, December 31, 2014 Volatility 90 % 87 % Expected Term (years) 0.12 1.10 Expected dividend yield — % — % Risk-free rate 0.65 % 0.26 % In addition to the assumptions above, the Company’s estimated fair value of the Series B Warrant liability is calculated using other key assumptions. Management, with the assistance of an independent valuation firm, makes these subjective determinations based on available current information; however, as such information changes, so might management’s determinations and such changes could have a material impact on future operating results. The net decrease in carrying amount of the Series B Warrants for the year ended December 31, 2015 was $16.6 million, of which $2.7 million was attributed to the change in fair value of the warrant liability during the three months ended December 31, 2015 and was recorded as other expense in the consolidated statement of operations. Factors contributing to the change in fair value of the warrants include the trading price of the Common Stock and term remaining to expiration of the warrants. During the year ended December 31, 2015, certain holders of Series B warrants cashless exercised a total of 1,713,045 warrants resulting in the issuance of 5,879,560 shares of Common Stock and the derecognition of approximately $12.5 million, in Series B Warrant liability, respectively for the year ended December 31, 2015, which was recorded as additional paid-in capital. Series C Warrants On March 5, 2015, the Company entered into separate agreements with certain Series B Warrant holders, who agreed to exercise their Series B Warrants to purchase an aggregate of 589,510 shares of the Company’s Common Stock at an exercise price of $6.50 per share, resulting in the de-recognition of $6.7 million of Series B warrant liability and gross proceeds to the Company of approximately $3.8 million based on the exercise price of the Series B warrants. In connection with this exercise of the Series B Warrants, the Company issued to each investor who exercised Series B Warrants, new Series C Warrants for the number of shares of the Company’s Common Stock underlying the Series B Warrants that were exercised. Each Series C Warrant is exercisable at $6.25 per share and will expire on March 5, 2020. The Company has calculated the fair value of the Series C warrants using a Black-Scholes pricing model, which requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs: December 31, March 5, 2015 Volatility 90 % 86 % Expected Term (years) 4.17 5.00 Expected dividend yield — % — % Risk-free rate 1.76 % 1.35 % In April 2015, the Company issued a tender offer to the remaining holders of Series B warrants to induce the holders to cash exercise the outstanding Series B warrants in exchange for new Series C Warrants with an exercise price of $6.25 per share that expire on March 5, 2020. The tender offer was extended to warrant holders under a registration statement filed with the SEC on Form S-4, which was declared effective on June 25, 2015 and expired on July 24, 2015. During July 2015, certain Series B warrant holder(s) tendered their Series B Warrants under the tender offer, which resulted in the issuance of 905 shares of Capnia Common Stock, the issuance of 905 Series C Warrants and proceeds to the Company of $5,882. The new Series C Warrants are exercisable into 590,415 shares of the Company’s Common Stock. As of December 31, 2015, the fair value of the Series C Warrants was determined to be $0.5 million. The decline in the fair value of the warrants of $2.6 million in the year ended December 31, 2015 was recorded as other income in the consolidated statement of operations.

Credit Facility

Credit Facility	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Credit Facility	Note 7. Credit Facility On September 29, 2014, the Company established a line of credit in the amount of up to $0.1 million. The line of credit bears a fixed interest rate of 6.0% per annum simple interest. The line of credit has a two-year repayment term, with prepayment at the Company’s option with no penalty. The line of credit shall be payable out of cash received in the Company’s accounts receivable following the commencement of commercial sales. In October, 2014, the Company drew down the full amount of $0.1 million provided for by the line of credit. During the year ended December 31, 2015, the Company repaid the outstanding amounts borrowed under the line of credit.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Commitments and Contingencies Facility Leases On July 1, 2015 the Company executed a new four year non-cancelable operating lease agreement for 8,171 square feet of office space for its headquarters facility. The lease agreement provides for monthly lease payments of $23,300 beginning in September of 2015, with increases in the following three years. An additional 5,265 square feet of office space became part of the new lease agreement on March 1, 2016. The Company leases office space under a non-cancelable operating lease agreement which was set to expire in May 2015. On February 2, 2015, the Company signed an amendment to its lease agreement, extending the lease through June 2018. The amendment provides for monthly lease payments of $22,000 beginning in June 2015, with increases in the following two years. The Company subleased this facility in January 2016 and ceased use of the facility in March 2016 (See Note 4). The Company also leases approximately 2,100 square feet of office space for its operations in Ivyland, Pennsylvania under a month-to-month lease. Rent expense was $184 thousand and $62 thousand during the three months ended March 31, 2016 and 2015, respectively. Contingencies In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In connection with the acquisition of the assets of NFG, the Company agreed to pay the former NFG shareholder an annual royalty payment for a period of 36 months. The agreement to pay the annual royalty resulted in the recognition of a contingent consideration, which is recognized at the inception of the transaction, and subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. Based on the assumptions, the fair value of the royalty was determined to be $153 thousand at the date of acquisition and $172 thousand at March 31, 2016.	Note 8. Commitments and Contingencies Facility Leases On July 1, 2015 the Company executed a new four year non-cancelable operating lease agreement for 8,171 square feet of office space for its headquarters facility. The lease agreement provides for monthly lease payments of $23,300 beginning in September of 2015, with increases in the following three years. An additional 5,265 square feet of office space became part of the new lease agreement on March 1, 2016 (see Note 15). The Company leases office space under a non-cancelable operating lease agreement which was set to expire in May 2015. On February 2, 2015, the Company signed an amendment to its lease agreement, extending the lease through June 2018. The amendment provides for monthly lease payments of $22,000 beginning in June 2015, with increases in the following two years. The Company subleased this facility in January 2016 (see Note 15). The Company also leases approximately 2,100 square feet for its operations in Ivyland, Pennsylvania under a month-to-month lease (see Note 15). Minimum rental commitments under all noncancelable leases with an initial term in excess of one year as of December 31, 2015 were as follows: Year ending December 31: Operating Leases 2016 $ 698,945 2017 750,118 2018 629,923 2019 334,747 Total $ 2,413,733 The table above does not consider the impact of lease payments the Company will receive under the sublease executed in January 2016 (see Note 15). Rent expense was $375,000 and $230,000 during the years ended December 31, 2015 and 2014, respectively. Contingencies In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. In connection with the acquisition of the assets of NeoForce, the Company agreed to pay the former NeoForce shareholder an annual royalty payment for a period of 36 months. The agreement to pay the annual royalty resulted in the recognition of a contingent consideration, which is recognized at the inception of the transaction, and subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. Based on the assumptions, the fair value of the Royalty was determined to be $153,000 at the date of acquisition and at December 31, 2015 (see Note 13).

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Capital Stock	Note 9. Capital Stock Common Stock: The Company is authorized to issue 100,000,000 shares of common stock as of December 31, 2014 with a par value of $0.001 per share. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the Board of Directors, subject to the prior rights of all classes of stock outstanding. The holders of common stock, voting as a separate class, are entitled to elect one member of the Board of Directors. Convertible Preferred Stock The Company is authorized to issue 40,000 shares of Series A Convertible Preferred Stock. The Company has issued 4,555 Series A Convertible Preferred Stock, with a par value of $0.001 and a stated value of 1,000 per share. The Series A Convertible Preferred Stock do not have an expiration date and are not redeemable. The Series A Convertible Preferred Stock was classified as permanent equity on the Company’s consolidated balance sheet in accordance with authoritative guidance for the classification and measurement of hybrid securities and distinguishing liability from equity instruments. The preferred stock is not redeemable at the option of the holder. Further, the Company evaluated its Series A Convertible Preferred Stock and determined that it is considered an equity host under ASC 815, Derivatives and Hedging The Company accounts for the Series A Convertible Preferred Stock in accordance with the guidance in ASC 815 Derivatives and Hedging The Company evaluated the liquidated damages provisions in the terms of this securities agreement and determined that it is probable that the Company will maintain an effective registration statement and have sufficient shares upon conversion and has therefore not recorded a liability for potential liquidated damages.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stockholders' Equity (Deficit)	Note 10. Stockholders’ Equity (Deficit) Stock Option Plan The Company has adopted the 1999 Incentive Stock Plan, the 2010 Equity Incentive Plan, and the 2014 Equity Incentive Plan (together, the Plans). The 1999 Incentive Stock Plan expired in 2009, and the 2010 Equity Incentive Plan has been closed to new issuances. Therefore, the Company may issue options to purchase shares of common stock to employees, directors, and consultants only under the 2014 Equity Incentive Plan. Options granted under the 2014 Plan may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees and directors. NSOs may be granted to employees, directors, advisors, and consultants. The Board of Directors has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value for an ISO or 85% of fair value for an NSO. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. The vesting period is normally monthly over a period of 4 years from the vesting date. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The Company recognized stock-based compensation expense related to options granted to employees for the fiscal years ended December 31, 2015 and 2014 of $942,369 and $345,435, respectively. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the statements of operations for stock-based compensation arrangements as of December 31, 2015 and December 31, 2014. Stock compensation expense was allocated between departments as follows; Year ended December 31, December 31, Research & Development $ 148,948 $64,020 Sales & Marketing 62,533 8,335 General & Administrative 730,888 273,080 Total $ 942,369 $ 345,435 The Company granted options to purchase 955,713 and 926,384 of the Company’s common stock in 2015 and 2014. The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions for the year ended December 31, 2015: Year Ended December 31, December 31, Expected life (years) 6.1 5.8 - 6.1 Risk-free interest rate 1.6% - 1.7 % 1.6% - 1.8 % Volatility 56% - 66 % 43% - 59 % Dividend rate — % — % Expected volatility is based on volatilities of a group of public companies operating in the Company’s industry. The expected life of stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. The Company has elected to use the simplified method, as the Company does not have enough historical exercise experience to provide a reasonable basis upon which to estimate the expected term and the stock option grants are considered “plain vanilla” options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The following table summarizes stock option transactions for the years ended December 31, 2015 and 2014 as issued under the Plans: Shares Number of Weighted- Weighted Balance at December 31, 2013 124,824 239,606 $ 3.36 2014 Plan authorized 1,437,165 — — Closed 2010 Plan (123,523 ) — — Options granted (926,384 ) 926,384 7.15 Options canceled/forfeited 93,979 (93,979 ) 6.75 Balance at December 31, 2014 606,061 1,072,011 6.34 8.67 Additional shares authorized 270,764 — — Options granted (955,713 ) 955,713 3.08 Options exercised — (83,848 ) 3.50 Options canceled/forfeited 85,037 (85,037 ) 5.03 Balance at December 31, 2015 6,149 1,858,839 $ 4.82 8.75 Options vested at December 31, 2014 — 578,889 $ 5.58 7.46 Options vested and expected to vest at December 31, 2014 — 1,072,011 $ 6.34 8.67 Options vested at December 31, 2015 — 922,927 $ 5.06 7.47 Options vested and expected to vest at December 31, 2015 — 1,858,839 $ 4.82 8.75 The weighted-average grant date fair value of employee options granted was $1.66 and $1.03 per share for the year ended December 31, 2015 and December 31, 2014, respectively. At December 31, 2015 total unrecognized employee stock-based compensation was $1,917,245, which is expected to be recognized over the weighted-average remaining vesting period of 2.5 years. As of December 31, 2015, the outstanding stock options had an intrinsic value of $67,165. The fair value of an equity award granted to a non-employee generally is determined in the same manner as an equity award granted to an employee. In most cases, the fair value of the equity securities granted is more reliably determinable than the fair value of the goods or services received. Stock-based compensation related to its grant of options to non-employees has not been material to date. 2014 Employee Stock Purchase Plan Our board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan, or the ESPP. The ESPP has become effective, and our board of directors will implement commencement of offers thereunder in its discretion. A total of 139,839 shares of our Common Stock has been made available for sale under the ESPP. In addition, our ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that our board of directors authorizes commencement, equal to the least of: • 1.0% of the outstanding shares of our Common Stock on the first day of such year; 279,680 shares; or • such amount as determined by our board of directors. As of December 31, 2015 there were no purchases by employees under this plan. Series D Warrants The Company has issued 1,280,324 Series D Warrants, with an exercise price of $2.46 and a term of five years expiring on October 15, 2020. The Company’s Series D Warrants contain standard anti-dilution provisions for stock dividends, stock splits, subdivisions, combinations and similar types of recapitalization events. They also contain a cashless exercise feature that provides for their net share settlement at the option of the holder in the event that there is no effective registration statement covering the continuous offer and sale of the warrants and underlying shares. The Company is required to comply with certain requirement to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Series D Warrant agreement further provides for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Series D Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration statement as described herein. The Company evaluated the registration payment arrangement stipulated in the terms of this securities agreement and determined that it is probable that the Company will maintain an effective registration statement and has therefore not allocated any portion of the proceeds to the registration payment arrangement. The Series D Warrant agreement specifically provides that under no circumstances will the Company be required to settle any Series D Warrant exercise for cash, whether by net settlement or otherwise. Accounting Treatment The Company accounts for the Series D Warrants in accordance with the guidance in ASC 815 Derivatives and Hedging Other Common Stock Warrants As of December 31, 2015, the Company had 480,147 Common Stock warrants outstanding from the 2010/2012 convertible notes, with an exercise price of $4.87 and a term of 10 years expiring in November 2024. During the year ended December 31, 2015, 43,720 Common Stock warrants were cashless exercised resulting in the issuance of 13,407 shares of the Company’s Common Stock. The Company also has outstanding 9,259 Common Stock warrants issued in 2009, with an exercise price of $21.60 and a term of 10 years, expiring in January 2019 and 82,500 Common Stock warrants issued to the underwriter in our IPO, with an exercise price of $7.14 and a term of 10 years, expiring in November 2024.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes Due to net losses in 2015 and 2014, the Company had no material current, deferred, or total income tax expense in the years ended December 31, 2015 and 2014. A reconciliation of income tax expense with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows: Years Ended December 31, 2015 2014 Tax on the loss before income tax expense computed at the federal statutory rate of 34% $ (5,408,551 ) $ (4,717,063 ) State tax (benefit) at statutory rate, net of federal benefit (928,107 ) (13,020 ) Change in Valuation Allowance 4,199,154 1,578,347 Change in research and development credits (60,991 ) 316,311 Change in fair value of warrants 1,493,215 2,960,766 Other 705,280 (125,341 ) Income tax expense $ — $ — Effective income tax rate — % — % Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31, 2015 and 2014: December 31, 2015 2014 Non-Current Deferred Tax Assets: Reserves and accruals $ 287,850 $ 71,953 Net Operating Loss Carryforwards 26,174,912 22,125,807 Research and development credits 1,381,296 1,345,833 Intangible Assets (74,113 ) 46,784 Fixed Assets 9,080 (10,505 ) Total Non-Current Deferred Tax Assets 27,779,025 23,579,872 Valuation Allowance (27,779,025 ) (23,579,872 ) Net Deferred Tax Assets $ — $ — The Company has recorded a full valuation allowance against its net deferred tax assets as it believes that it is more likely than not that such assets will not be realized. The valuation allowance increased by $4,199,154 from December 31, 2014 to December 31, 2015 primarily due to the generation of current year net operating losses and research and development credits claimed. As of December 31, 2015, the Company had $67,263,865 of federal and $56,650,176 of state net operating loss, respectively, available to offset future taxable income. The federal net operating loss carryforwards begins to expire in 2019 and the state net operating loss carryforwards will begin to expire in 2016, if not utilized. As of December 31, 2015, the Company also had $1,328,082 of federal and $977,574 of state research and development credit carryforwards, respectively. The federal research and development credit carryforward begins to expire in 2024 and the state research and development credit can be carried forward indefinitely. In addition, the use of net operating loss and tax credit carryforwards may be limited under Section 382 of the Internal Revenue Code in certain situations where changes occur in the stock ownership of a company. In the event that the Company has had a change in ownership, utilization of the carryforwards could be restricted. The following tables summarize the activities of gross unrecognized tax benefits: December 31, 2015 2014 Beginning balance 673,247 — Increase related to prior year tax positions — 628,383 Decreases related to prior year tax positions (13,207 ) — Increase related to Current year tax positions 31,657 44,864 Decreases related to current year tax positions — — Ending Balance $ 691,697 $ 673,247 The amount of unrecognized tax benefits that would impact the effective tax rate were approximately none and none as of December 31, 2015 and December 31, 2014, respectively. As of December 31, 2015, $691,697 of unrecognized tax benefits would be offset by a change in valuation allowance. The Company files income tax returns in the U.S. federal jurisdiction and certain state jurisdictions. In the normal course of business, the Company is subject to examination by federal, state and local jurisdictions, where applicable. In the U.S federal jurisdiction, tax years 1999 forward remain open to examination, and in the state tax jurisdiction, years 2005 forward remain open to examination. The Company is currently not under audit by any federal, state or local jurisdiction. During November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes The Protecting Americans from Tax Hikes (PATH) Act (“Act”) (H.R 2029) was signed into law on December 18, 2015. The Act contains a number of provisions including, most notably, permanent extension of the United States federal research tax credit. The Act did not have a material impact on the Company’s effective tax rate for fiscal 2015 due to the effect of the valuation allowance on the Company’s deferred tax assets. The Company uses the “more likely than not” criterion for recognizing the tax benefit of uncertain tax positions and to establish measurement criteria for income tax benefits. The Company has determined it has no material unrecognized assets or liabilities related to uncertain tax positions as of December 31, 2015. The Company does not anticipate any significant changes in such uncertainties and judgments during the next 12 months. In the event the Company should need to recognize interest and penalties related to unrecognized tax liabilities, this amount will be recorded as a component of other expense.

Net loss per share

Net loss per share	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net loss per share	Note 8. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of Common Stock actually outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of Common Stock outstanding and dilutive potential Common Stock that would be issued upon the exercise of Common Stock warrants and options. For the three months ended March 31, 2016 and 2015, the effect of issuing the potential common stock is anti-dilutive due to the net losses in those periods and the number of shares used to compute basic and diluted earnings per share are the same in each of those periods. The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in Common Stock equivalent shares): As of March 31, 2016 2015 Convertible preferred stock 4,505,405 — Warrants issued to 2010/2012 convertible note holders to purchase common stock 480,147 480,147 Options to purchase common stock 2,297,639 1,458,964 Warrants issued in 2009 to purchase common stock 9,259 9,259 Warrants issued to underwriter to purchase common stock 82,500 82,500 Series A Warrants to purchase common stock 2,425,605 2,425,605 Series B Warrants to purchase common stock — 1,778,275 Series C Warrants to purchase common stock 590,415 589,510 Series D Warrants to purchase common stock 2,810,812 —	Note 12. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of Common Stock actually outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of Common Stock outstanding and dilutive potential Common Stock that would be issued upon the exercise of Common Stock warrants and options. For the year ended December 31, 2015 and 2014, the effect of issuing the potential common stock is anti-dilutive due to the net losses in those periods and the number of shares used to compute basic and diluted earnings per share are the same in each of those periods. The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in Common Stock equivalent shares): As of December 31, 2015 2014 Convertible preferred stock 2,462,162 — Warrants issued to 2010/2012 convertible note holders to purchase common stock 480,147 523,867 Options to purchase common stock 1,858,839 1,072,011 Warrants issued in 2009 to purchase common stock 9,259 9,259 Warrants issued to underwriter to purchase common stock 82,500 82,500 Series A warrants to purchase common stock 2,425,605 2,449,605 Series B warrants to purchase common stock 116,580 2,449,605 Series C warrants to purchase common stock 590,415 — Series D warrants to purchase common stock 1,280,324 —

NeoForce Group, Inc. Acquisitio

NeoForce Group, Inc. Acquisition	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
NeoForce Group, Inc. Acquisition	Note 13. NeoForce Group, Inc. Acquisition On September 8, 2015, the Company through its wholly owned subsidiary Neoforce, Inc (“NFI”), acquired substantially all of the assets of NeoForce in exchange for an upfront cash payment of $1.0 million. In addition, the Company agreed to pay the former NeoForce shareholder an annual royalty payment for a period of 36 months (“Royalty”) in the low single digits based on net sales of NeoForce products that were acquired by the Company. As of December 31, 2015, the Company recorded $8,372 of Royalty payable. The acquisition of NeoForce strengthens the Company’s commitment to leveraging technology to address unmet needs in neonatology, which is a high growth segment in the healthcare business. The Company plans to leverage the expertise and hospital relationships of NeoForce to accelerate the adoption of CoSense. The transaction has been accounted for as a business combination under the acquisition method of accounting. Accordingly, the tangible assets and identifiable intangible assets acquired and liabilities assumed have been recorded at fair value, with the remaining purchase price recorded as goodwill. The fair values of current assets and liabilities approximated their book value. The fair values of acquired assets and liabilities are based on preliminary cash flow projections and other assumptions. The fair values of acquired intangible assets were determined using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The agreement to pay the annual Royalty resulted in the recognition of a contingent consideration, which is recognized at the inception of the transaction, and subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. Based on the assumptions, the fair value of the Royalty was determined to be $153,000 at the date of acquisition and at December 31, 2015. The fair value of the royalty was determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate of 20% commensurate with the Company’s cost of capital and expectation of the revenue growth for products at their life cycle stage. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The aggregate purchase price consideration was as follows: Cash consideration $ 1,000,000 Fair value of contingent consideration 153,000 Total purchase price consideration $ 1,153,000 The fair values of assets acquired at the transaction date are summarized below: Net tangible assets acquired $ 39,377 Customer contracts 259,730 Patents 135,890 Goodwill 718,003 Net Assets Acquired $ 1,153,000 Net tangible assets acquired consisted primarily of equipment, furniture and fixtures. Goodwill is an unidentifiable asset and, as such, can only be measured as a residual. A significant component of the NeoForce goodwill, which did not meet the criteria for separate recognition as an intangible asset was a skilled and assembled workforce. The founder of NeoForce, who became the General Manager of Neonatology at the Company, brings 25 years of medical device sales, operations and product development experience at neonatology focused companies. The Company plans to use his expertise and broad relationships with top tier hospitals across the United States to accelerate the adoption of CoSense. The Company also expects to achieve synergies in the areas of accounting, informational technology, sales & marketing and other general administration expenses through the combination. Pro Forma Financial Information (Unaudited) The following table presents the unaudited pro forma results of Capnia, Inc. (including the operations of Neoforce) for the years ended December 31, 2014 and December 31, 2015. The unaudited pro forma financial information combines the results of operations of Capnia and NeoForce as though the companies had been combined as of the beginning of each of the fiscal periods presented. As of September 8, 2015, the date of the acquisition, the results of NFI have been combined with Capnia as a wholly-owned subsidiary. The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the consolidated results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2014 or 2015. In addition, the unaudited pro forma financial information does not attempt to project the future consolidated results of operations. December 31, December 31, 2015 2014 Pro forma total revenues $ 1,168,846 $ 987,853 Pro forma net loss $ (16,002,126 ) $ (13,307,030 ) Pro forma net loss per share — basic and diluted $ (1.70 ) $ (10.48 ) Pro forma weighted — average shares — basic and diluted 9,425,880 1,270,033 The unaudited pro forma financial information above reflects the following: • the increase of amortization expense of $53,000 in the years ended December 31, 2015 and 2014 related to the estimated fair value of intangible assets from the purchase price allocation which are being amortized over their estimated useful lives through 2028. The change in depreciation expense related to the change in estimated fair value of property and equipment from the book value at the time of the acquisition was not material. For the year ended December 31, 2015, NeoForce, Inc. revenue and net income included in the Company’s Consolidated Statement of Operations and Net Loss were $279,000 and $76,000, respectively.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan	Note 14. Defined Contribution Plan The Company sponsors a 401(k) Plan, which stipulates that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations of eligible compensation. The Company may match employee contributions in amounts to be determined at the Company’s sole discretion. To date, the Company has not made any matching contributions.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 9. Subsequent Events On April 26, 2016, the Company commercially launched Serenz in the E.U. over the counter through two United Kingdom-based pharmacy chains, Paydens Group (Paydens) and Weldricks Pharmacy Limited (Weldricks), with more than 150 retail pharmacy locations in the United Kingdom.	Note 15. Subsequent Events On January 5, 2016, January 27, 2016 and March 16, 2016, the two funds managed by Sabby converted 1,665 shares of their Series A Convertible Stock into 900,000 shares of Common Stock. On January 8, 2016, the Company completed the second closing under the Sabby Purchase Agreement entered into on October 12, 2015 with funds managed by Sabby. The Company issued 5,445 shares of Series A Convertible Preferred Stock with a stated value of $1,000 per share and par value of $0.001. In addition, the Company issued 1,471,622 Series D Warrants to the funds managed by Sabby and 58,865 Series D Warrants to Maxim Group, LLC as underwriter. The Company received proceeds of approximately $5 million, net of $0.5 million in estimated expenses. On January 11, 2016, the Company received a letter from Nasdaq indicating that the Company had regained compliance with the Nasdaq Listing Requirements. On January 13, 2016, the Company entered into agreement to sublease its old office space at 3 Twin Dolphin Dr. The Company occupied this space as its corporate headquarters until August 1, 2015. On January 26, 2016, the Company entered into a distribution agreement with Bemes, Inc., a leading medical equipment Master Distributor, to market and distribute CoSense and Precision Sampling Sets. Under the terms of the agreement, Bemes will have the exclusive right for sales, marketing, distribution and field service activities for CoSense in the United States. On February 12, 2016, the Series B Warrants expired. On December 31, 2015, the Company had 116,580 Series B Warrants outstanding. Subsequent to December 31, 2015, a number of different Series B warrant holders exercised on a cashless basis 102,300 Series B Warrants and as a result the Company issued 485,202 shares of Common Stock. The remaining 14,280 Series B Warrants expired on February 12, 2016. On February 12, 2016, the Company entered into an amendment and extension of its lease dated January 13, 2006 at 35 Commerce Drive in Ivyland, Pennsylvania. The amendment and extension effective as of March 1, 2016, includes additional space at 34 Commerce Drive and expires on March 31, 2017.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity	Note 7. Stockholders’ Equity Convertible Preferred Stock The Company is authorized to issue 40,000 shares of Series A Convertible Preferred Stock. On January 8, 2016 the Company issued an aggregate of 5,445 shares of Series A Convertible Preferred Stock under the Sabby Purchase Agreement. The Company has issued a total of 10,000 Series A Convertible Preferred Stock, with a par value of $0.001 and a stated value of $1,000 per share. The Series A Convertible Preferred Stock do not have an expiration date and are not redeemable. During the three months ended March 31, 2016, the holders of the Series A Convertible Preferred Stock converted 1,665 shares of Series A Convertible Preferred Stock resulting in the issuance of 900,000 shares of Common Stock. Stock Option Plan The Company has adopted the 1999 Incentive Stock Plan, the 2010 Equity Incentive Plan, and the 2014 Equity Incentive Plan (together, the “Plans”). The 1999 Incentive Stock Plan expired in 2009, and the 2010 Equity Incentive Plan has been closed to new issuances. Therefore, the Company may issue options to purchase shares of common stock to employees, directors, and consultants only under the 2014 Equity Incentive Plan. Options granted under the 2014 Plan may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees and directors. NSOs may be granted to employees, directors, advisors, and consultants. The Board of Directors has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value for an ISO or 85% of fair value for an NSO. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. The vesting period is normally monthly over a period of 4 years from the vesting date. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The Company recognized stock-based compensation expense related to options granted to employees for the three months ended March 31, 2016 and 2015 of $136 thousand and $401 thousand, respectively. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the statements of operations for stock-based compensation arrangements as of March 31, 2016 and March 31, 2015. Stock compensation expense (in thousands) was allocated between departments as follows: Three months ended March 31, 2016 2015 Research & Development $ 33 $ 50 Sales & Marketing (31 ) 20 General & Administrative 134 331 Total $ 136 $ 401 The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Three Months Ended March 31, 2016 2015 Expected life (years) 6.0 - 6.1 5.5 - 6.1 Risk-free interest rate 1.5% - 1.7% 1.5% - 1.6% Volatility 66% - 67% 57% - 68% Dividend rate —% —% Expected volatility is based on volatilities of a group of public companies operating in the Company’s industry. The expected life of stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. The Company has elected to use the simplified method, as the Company does not have enough historical exercise experience to provide a reasonable basis upon which to estimate the expected term and the stock option grants are considered “plain vanilla” options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The following table summarizes stock option transactions issued under the Plans: Shares Number of Weighted- Weighted (in years) Balance at December 31, 2014 606,061 1,072,011 6.34 8.67 Additional shares authorized 270,764 Options granted (955,713 ) 955,713 3.08 Options exercised (83,848 ) 3.50 Options canceled/forfeited 85,037 (85,037 ) 5.03 Balance at December 31, 2015 6,149 1,858,839 4.82 8.75 Additional shares authorized 560,717 Options granted (538,500 ) 538,500 1.59 Options exercised — — Options canceled/forfeited 99,700 (99,700 ) 2.33 Balance at March 31, 2016 128,066 2,297,639 $ 4.09 8.77 Future stock-based compensation for unvested employee options granted and outstanding as of March 31, 2016 is approximately $1.8 million to be recognized over a remaining requisite service period of 3.2 years. The fair value of an equity award granted to a non-employee generally is determined in the same manner as an equity award granted to an employee. In most cases, the fair value of the equity securities granted is more reliably determinable than the fair value of the goods or services received. Stock-based compensation related to its grant of options to non-employees has not been material to date. 2014 Employee Stock Purchase Plan Our Board of Directors and stockholders have adopted the 2014 Employee Stock Purchase Plan, or the ESPP. The ESPP has become effective, and our Board of Directors will implement commencement of offers thereunder in its discretion. A total of 139,839 shares of our Common Stock has been made available for sale under the ESPP. In addition, our ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that our Board of Directors authorizes commencement, equal to the least of: • 1.0% of the outstanding shares of our Common Stock on the first day of such year; 279,680 shares; or • such amount as determined by our Board of Directors. As of March 31, 2016 there were no purchases by employees under this plan. Series D Warrants The Company has issued 2,810,811 Series D Warrants, with an exercise price of $2.46 and a term of five years expiring on October 15, 2020. The Company’s Series D Warrants contain standard anti-dilution provisions for stock dividends, stock splits, subdivisions, combinations and similar types of recapitalization events. They also contain a cashless exercise feature that provides for their net share settlement at the option of the holder in the event that there is no effective registration statement covering the continuous offer and sale of the warrants and underlying shares. The Company is required to comply with certain requirement to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Series D Warrant agreement further provides for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Series D Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration statement as described herein. The Company evaluated the registration payment arrangement stipulated in the terms of this securities agreement and determined that it is probable that the Company will maintain an effective registration statement and has therefore not allocated any portion of the proceeds to the registration payment arrangement. The Series D Warrant agreement specifically provides that under no circumstances will the Company be required to settle any Series D Warrant exercise for cash, whether by net settlement or otherwise. Accounting Treatment The Company accounts for the Series D Warrants in accordance with the guidance in ASC 815 Derivatives and Hedging Other Common Stock Warrants As of March 31, 2016, the Company had 480,147 Common Stock warrants outstanding from the 2010/2012 convertible notes, with an exercise price of $4.87 and a term of 10 years expiring in November 2024. The Company also has outstanding 9,259 Common Stock warrants issued in 2009, with an exercise price of $21.60 and a term of 10 years, expiring in January 2019 and 82,500 Common Stock warrants issued to the underwriter in our IPO, with an exercise price of $7.14 and a term of 10 years, expiring in November 2024.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the Company’s financial position as of March 31, 2016 and results of its operations and cash flows for the three months ended March 31, 2016 and 2015. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. Certain prior period amounts have been reclassified to conform to current period presentation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K.	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”).
Principles of Consolidation		Principles of Consolidation The consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, liability and equity instruments, stock-based compensation, acquired intangibles, contingent earn-out consideration, and allowances for accounts receivable and inventory.	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of liabilities and equity instruments, stock-based compensation, value and life of acquired intangibles, and allowances for accounts receivable and inventory.
Concentration of Credit Risk		Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at two commercial banks that management believes are of high credit quality. Cash and cash equivalents deposited with these commercial banks exceeded the Federal Deposit Insurance Corporation insurable limit at December 31, 2015 and December 31, 2014. The Company expects this to continue.
Segments		Segments The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting, making operating decisions, and assessing financial performance. All long-lived assets are maintained in the United States of America.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly liquid investments, including its money market fund, purchased with an original maturity of three months or less to be cash equivalents. The Company’s cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market fund which was unrestricted as to withdrawal or use.
Accounts Receivable		Accounts Receivable Accounts receivable as of December 31, 2015 consist of balances due from customers in the normal course of business. The Company did not record an allowance for doubtful accounts as this balance was deemed fully collectible.
Prepaid Expenses and Other Current Assets		Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of payments primarily related to insurance and short-term deposits. Prepaid expenses are initially recorded upon payment and are expensed as goods or services are received.
Inventory	Inventory Inventory is stated at the lower of cost or market under the first-in, first-out (FIFO) method.	Inventory Inventory as of December 31, 2014 consisted of raw materials to be used in the manufacture of our products. As of December 31, 2015, the Company’s inventory includes approximately $106,000 of raw material, $398,000 of work-in-process and $46,000 of finished goods. Inventory is stated at the lower of cost or market under the first-in, first-out (FIFO) method.
Intangible Assets	Intangible Assets Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 5 to 12 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life.	Intangible Assets Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 5 to 12 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life.
Business Combinations		Business Combinations For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.
Property and Equipment, Net		Property and Equipment, Net Property and equipment are stated at cost net of accumulated depreciation and amortization calculated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.
Long-Lived Assets		Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value.
Goodwill	Goodwill The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. There was no impairment of goodwill for the three months ended March 31, 2016. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.	Goodwill The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. There was no impairment of goodwill for the year ended December 31, 2015. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.
Revenue Recognition		Revenue Recognition The Company began recognizing sales of CoSense during the year ended December 31, 2015. In addition, the Company began recognizing sales of NFI pulmonary resuscitation products after the acquisition of Neoforce’s assets in September 2015. The Company recognizes revenue when all of the following criteria are met: • persuasive evidence of an arrangement exists; • the sales price is fixed or determinable; • collection of the relevant receivable is probable at the time of sale; and • delivery has occurred or services have been rendered. For a majority of sales, where the Company delivers its product to hospitals or medical facilities, the Company recognizes revenue upon delivery, which represents satisfaction of the required revenue recognition criteria. The Company does not offer rights of return or price protection and it has no post-delivery obligations. The Company offers a limited one-year warranty to most customers. Estimated warranty obligations are recorded at the time of sale and to date, warranty costs have been insignificant. The Company also recognized revenue related to a government grant awarded during the year ended December 31, 2015. Government grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. Revenue related to government grants is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable performance obligations under the government grants have been met. Funds received under government grants are recorded as revenue if the Company is deemed to be the principal participant in the contract arrangements because the activities under the contracts are part of the Company’s development programs. If the Company is not the principal participant, the funds from government grants are recorded as a reduction to research and development expense. Funds received from government grants are not refundable and are recognized when the related qualified research and development expenses are incurred and when there is reasonable assurance that the funds will be received.
Research and Development		Research and Development Research and development costs are charged to operations as incurred. Research and development costs consist primarily of salaries and benefits, consultant fees, prototype expenses, certain facility costs and other costs associated with clinical trials, net of reimbursed amounts. Research and development costs include costs of $220,000 incurred and reimbursed under the government grant awarded in the year ended December 31, 2015. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred.
Income Taxes		Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the amounts at which assets and liabilities are recorded for financial reporting purposes and the amounts recorded for income tax purposes. Deferred income taxes are classified as current or non-current, based on the classifications of the related assets and liabilities giving rise to the temporary differences. A valuation allowance is provided against the Company’s deferred income tax assets when their realization is not reasonably assured. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.
Convertible Preferred Stock and other Hybrid Instruments		Convertible Preferred Stock and other Hybrid Instruments The Company’s convertible preferred stock was classified as permanent equity on its balance sheet in accordance with authoritative guidance for the classification and measurement of hybrid securities and distinguishing liability from equity instruments. The preferred stock is not redeemable at the option of the holder. Further, the Company evaluated its Series A Convertible Preferred Stock and determined that it is considered an equity host under ASC 815, Derivatives and Hedging
Common Stock Purchase Warrants and Other Derivative Financial Instruments	Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies Common Stock purchase warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company determined that certain freestanding derivatives, which principally consist of Series A, Series B, and Series C Warrants to purchase Common Stock, do not satisfy the criteria for classification as equity instruments due to the existence of certain cash settlement features that are not within the sole control of the Company or variable settlement provision that cause them to not be indexed to the Company’s own stock. Due to certain provisions contained in the Series B Warrant agreement that provides for the Company potentially issuing an unlimited number of shares upon exercise, the Company had adopted a sequencing policy that reclassified contracts, with the exception of stock options, from equity to assets or liabilities for those with the latest inception date first. The Company had evaluated the issuance of securities as to reclassification as a liability under this sequencing policy through February 12, 2016, the date that the Series B Warrants expired.	Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies Common Stock purchase warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company determined that certain freestanding derivatives, which principally consist of Series A, Series B, and Series C warrants to purchase Common Stock, do not satisfy the criteria for classification as equity instruments due to the existence of certain cash settlement features that are not within the sole control of the Company or variable settlement provision that cause them to not be indexed to the Company’s own stock. The Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the latest inception date first. Future issuance of securities will be evaluated as to reclassification as a liability under our sequencing policy of latest inception date first until either all of the Series B warrants are settled or expire.
Stock-Based Compensation		Stock-Based Compensation For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the estimated fair value on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model, as they are earned. The awards generally vest over the time period the Company expects to receive services from the non-employee.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended March 31, 2016 as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 that are of significance or potential significance to the Company.	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. In April 2015, the Financial Accounting Standards Board (FASB) issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU No. 2016-02, Leases. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.
Patents [Member]
Intangible Assets		Patent On June 30, 2015, the Company entered into an amendment of the BDDI Asset Purchase Agreement (the “BDDI Amending Agreement”), under which the Company committed to pay aggregate cash payments of $450,000 and issued 40,000 shares of Common Stock to an affiliate of BDDI. With respect to the aggregate cash payments of $450,000, the Company paid an affiliate of BDDI an initial sum of $150,000 on July 1, 2015, and is obligated to pay $100,000 on each of the six, twelve and eighteen-month anniversaries of the signing of the amended agreement. The Company made the first installment of $100,000 on December 21, 2015. The remaining $200,000 payable under this agreement has been included in Accrued compensation and other current liabilities on the balance sheet. Under the original Asset Purchase Agreement dated June 11, 2010, the Company purchased a patent for Breath End Tidal Gas Monitor. The patent was issued on June 19, 2003 and expires on August 1, 2027. The Company has capitalized the fair value of the patent purchased as an intangible asset on its consolidated balance sheet, and is amortizing the fair value over the remaining useful life of the patent. In July 2015, the Company also entered into a consulting agreement with an affiliate of BDDI. As part of this consulting agreement the Company issued 10,000 shares to the affiliate of BDDI.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Intangible Assets		Intangible assets consist of the following at December 31, 2015: Amount Accumulated Net Amount Useful Lives Patents and trademarks $ 697,890 $ (32,155 ) $ 665,735 5-12 Customer contracts 259,730 (8,658 ) 251,072 10.00 Total $ 957,620 $ (40,813 ) $ 916,807
Schedule of Future Amortization Expense		Future amortization expense for intangible assets over their remaining useful lives is as follows: Year ending December 31: Patents and Customer contracts Total Amortization 2016 $ 73,370 $ 25,973 $ 99,343 2017 73,370 25,973 99,343 2018 73,370 25,973 99,343 2019 73,370 25,973 99,343 2020 and thereafter 372,255 147,180 519,435 Total $ 665,735 $ 251,072 $ 916,807
Schedule of Inventory	As of December 31, 2015 and March 31, 2016, the Company’s inventory was comprised of the following (in thousands): March 31, December 31, Raw materials $ 290 $ 106 Work-in-process 267 399 Finished goods 96 46 Total inventory $ 653 $ 551

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements at March 31, 2016 Total Level 1 Level 2 Level 3 Assets Money market fund $ 3,975 $ 3,975 $ — $ — Liabilities Series A warrant liability $ 558 $ 558 $ — $ — Series C warrant liability 219 — — 219 Total liabilities $ 777 $ 558 $ — $ 219 Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets Money market fund $ 3,804 $ 3,804 $ — $ — Liabilities Series A warrant liability $ 1,213 $ 1,213 $ — $ — Series B warrant liability 865 — — 865 Series C warrant liability 462 — — 462 Total common stock warrant liability $ 2,540 $ 1,213 $ — $ 1,327	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements at December 31, 2015 Total Level 1 Level 2 Level 3 Assets Money market fund $ 3,803,929 $ 3,803,929 — — Liabilities Series A warrant liability 1,212,803 1,212,803 — — Series B warrant liability 865,000 — — 865,000 Series C warrant liability 462,437 — — 462,437 Total common stock warrant liability $ 2,540,240 $ 1,212,803 — $ 1,327,437 Fair Value Measurements at December 31, 2014 Total Level 1 Level 2 Level 3 Assets Money market fund $ 7,891,888 $ 7,891,888 $ — $ — Liabilities Series A warrant liability 857,362 857,362 — — Series B warrant liability 17,438,731 — — 17,438,731 Total common stock warrant liability $ 18,296,093 $ 857,362 — $ 17,438,731
Summary of Changes in Fair Value of Level1 and Level 3 Financial Instruments	The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 and Level 3 warrants, which are treated as liabilities, as follows (dollars in thousands): Series A Warrant Series B Warrant Series C Warrant Number of Liability Number of Liability Number of Liability Balance at December 31, 2015 2,425,605 $ 1,213 116,580 $ 865 590,415 $ 462 Change in value of Series A Warrants — (655 ) — — — — De-recognition of Series B Warrant liability upon cashless exercise of warrants (485,202 shares issued) — — (102,300 ) (593 ) — — De-recognition of Series B Warrant liability upon expiration — — (14,280 ) — — — Change in value of Series B Warrants — — — (272 ) — — Change in value of Series C Warrants — — — — — (243 ) Balance at March 31, 2016 2,425,605 $ 558 — $ — 590,415 $ 219	The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 and Level 3 financial instruments, which are treated as liabilities, as follows: Series A Warrant Series B Warrant Series C Warrant Number of Liability Number of Liability Number of Liability Balance at December 31, 2014 2,449,605 $ 857,362 2,449,605 $ 17,438,731 — $ — Change in value of Series A Warrants — 397,441 — — — — De-recognition of Series A Warrant liability upon exercise (24,000 ) (42,000 ) — — — — De-recognition of Series B Warrant liability upon cash exercise of 619,512 warrants in Private Transaction (619,512 shares issued) — — (619,512 ) (6,747,765 ) — — De-recognition of Series B Warrant liability upon cashless exercise of 1,713,045 warrants (5,879,560 shares issued) — — (1,713,045 ) (12,527,991 ) — — De-recognition of Series B Warrant liability upon contribution of 468 warrants back to the Company — — (468 ) (3,332 ) — — Change in value of Series B Warrants — — — 2,705,357 — — Record Series C Warrant Liability as inducement charge (589,510 warrants in Private Transaction, 905 warrants in tender offer) — — — — 590,415 3,049,375 Change in value of Series C Warrants — — — — — (2,586,938 ) Balance at December 31, 2015 2,425,605 $ 1,212,803 116,580 $ 865,000 590,415 $ 462,437

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment consisted of the following: December 31, December 31, Furniture and fixtures $ 236,366 $ 180,238 Computer hardware 52,112 27,555 Leasehold improvements 9,117 10,726 $ 297,595 $ 218,519 Less accumulated depreciation and amortization (211,850 ) (160,912 ) Total $ 85,745 $ 57,607

Warrant Liabilities (Tables)

Warrant Liabilities (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Fair Value of Convertible Preferred Stock Warrant Liability	The Company used the following inputs: March 31, December 31, Volatility 90 % 90 % Expected Term (years) 3.92 4.17 Expected dividend yield — % — % Risk-free rate 1.03 % 1.76 %
Series B Warrant [Member]
Fair Value of Convertible Preferred Stock Warrant Liability		As of December 31, 2015 and December 31, 2014 the Company used a Monte Carlo simulation to calculate the fair value of its Series B Warrant liability. This model is dependent upon several variables such as the warrant’s term, exercise price, current stock price, risk-free interest rate estimated over the contractual term, estimated volatility of our stock over the term of the warrant and the estimated market price of our stock during the cashless exercise period. The risk-free rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending the volatility rates for a number of similar publicly-traded companies. The Company used the following inputs: December 31, December 31, 2014 Volatility 90 % 87 % Expected Term (years) 0.12 1.10 Expected dividend yield — % — % Risk-free rate 0.65 % 0.26 %
Series C Warrant Liability [Member]
Fair Value of Convertible Preferred Stock Warrant Liability		The Company has calculated the fair value of the Series C warrants using a Black-Scholes pricing model, which requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs: December 31, March 5, 2015 Volatility 90 % 86 % Expected Term (years) 4.17 5.00 Expected dividend yield — % — % Risk-free rate 1.76 % 1.35 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Operating Leases of Lessee Disclosure	Minimum rental commitments under all noncancelable leases with an initial term in excess of one year as of December 31, 2015 were as follows: Year ending December 31: Operating Leases 2016 $ 698,945 2017 750,118 2018 629,923 2019 334,747 Total $ 2,413,733

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Based Compensation Expense	Stock compensation expense (in thousands) was allocated between departments as follows: Three months ended March 31, 2016 2015 Research & Development $ 33 $ 50 Sales & Marketing (31 ) 20 General & Administrative 134 331 Total $ 136 $ 401	Stock compensation expense was allocated between departments as follows; Year ended December 31, December 31, Research & Development $ 148,948 $64,020 Sales & Marketing 62,533 8,335 General & Administrative 730,888 273,080 Total $ 942,369 $ 345,435
Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model	The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Three Months Ended March 31, 2016 2015 Expected life (years) 6.0 - 6.1 5.5 - 6.1 Risk-free interest rate 1.5% - 1.7% 1.5% - 1.6% Volatility 66% - 67% 57% - 68% Dividend rate —% —%	The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions for the year ended December 31, 2015: Year Ended December 31, December 31, Expected life (years) 6.1 5.8 - 6.1 Risk-free interest rate 1.6% - 1.7 % 1.6% - 1.8 % Volatility 56% - 66 % 43% - 59 % Dividend rate — % — %
Summary of Stock Option Transactions	The following table summarizes stock option transactions issued under the Plans: Shares Number of Weighted- Weighted (in years) Balance at December 31, 2014 606,061 1,072,011 6.34 8.67 Additional shares authorized 270,764 Options granted (955,713 ) 955,713 3.08 Options exercised (83,848 ) 3.50 Options canceled/forfeited 85,037 (85,037 ) 5.03 Balance at December 31, 2015 6,149 1,858,839 4.82 8.75 Additional shares authorized 560,717 Options granted (538,500 ) 538,500 1.59 Options exercised — — Options canceled/forfeited 99,700 (99,700 ) 2.33 Balance at March 31, 2016 128,066 2,297,639 $ 4.09 8.77	The following table summarizes stock option transactions for the years ended December 31, 2015 and 2014 as issued under the Plans: Shares Number of Weighted- Weighted Balance at December 31, 2013 124,824 239,606 $ 3.36 2014 Plan authorized 1,437,165 — — Closed 2010 Plan (123,523 ) — — Options granted (926,384 ) 926,384 7.15 Options canceled/forfeited 93,979 (93,979 ) 6.75 Balance at December 31, 2014 606,061 1,072,011 6.34 8.67 Additional shares authorized 270,764 — — Options granted (955,713 ) 955,713 3.08 Options exercised — (83,848 ) 3.50 Options canceled/forfeited 85,037 (85,037 ) 5.03 Balance at December 31, 2015 6,149 1,858,839 $ 4.82 8.75 Options vested at December 31, 2014 — 578,889 $ 5.58 7.46 Options vested and expected to vest at December 31, 2014 — 1,072,011 $ 6.34 8.67 Options vested at December 31, 2015 — 922,927 $ 5.06 7.47 Options vested and expected to vest at December 31, 2015 — 1,858,839 $ 4.82 8.75

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Reconciliation of Income Tax Expense by Applying Statutory U.S. Federal Income Tax Rate to Income Before Income Taxes	A reconciliation of income tax expense with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows: Years Ended December 31, 2015 2014 Tax on the loss before income tax expense computed at the federal statutory rate of 34% $ (5,408,551 ) $ (4,717,063 ) State tax (benefit) at statutory rate, net of federal benefit (928,107 ) (13,020 ) Change in Valuation Allowance 4,199,154 1,578,347 Change in research and development credits (60,991 ) 316,311 Change in fair value of warrants 1,493,215 2,960,766 Other 705,280 (125,341 ) Income tax expense $ — $ — Effective income tax rate — % — %
Significant Components of Company's Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31, 2015 and 2014: December 31, 2015 2014 Non-Current Deferred Tax Assets: Reserves and accruals $ 287,850 $ 71,953 Net Operating Loss Carryforwards 26,174,912 22,125,807 Research and development credits 1,381,296 1,345,833 Intangible Assets (74,113 ) 46,784 Fixed Assets 9,080 (10,505 ) Total Non-Current Deferred Tax Assets 27,779,025 23,579,872 Valuation Allowance (27,779,025 ) (23,579,872 ) Net Deferred Tax Assets $ — $ —
Summary of Gross Unrecognized Tax Benefits	The following tables summarize the activities of gross unrecognized tax benefits: December 31, 2015 2014 Beginning balance 673,247 — Increase related to prior year tax positions — 628,383 Decreases related to prior year tax positions (13,207 ) — Increase related to Current year tax positions 31,657 44,864 Decreases related to current year tax positions — — Ending Balance $ 691,697 $ 673,247

Net loss per share (Tables)

Net loss per share (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding	The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in Common Stock equivalent shares): As of March 31, 2016 2015 Convertible preferred stock 4,505,405 — Warrants issued to 2010/2012 convertible note holders to purchase common stock 480,147 480,147 Options to purchase common stock 2,297,639 1,458,964 Warrants issued in 2009 to purchase common stock 9,259 9,259 Warrants issued to underwriter to purchase common stock 82,500 82,500 Series A Warrants to purchase common stock 2,425,605 2,425,605 Series B Warrants to purchase common stock — 1,778,275 Series C Warrants to purchase common stock 590,415 589,510 Series D Warrants to purchase common stock 2,810,812 —	The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in Common Stock equivalent shares): As of December 31, 2015 2014 Convertible preferred stock 2,462,162 — Warrants issued to 2010/2012 convertible note holders to purchase common stock 480,147 523,867 Options to purchase common stock 1,858,839 1,072,011 Warrants issued in 2009 to purchase common stock 9,259 9,259 Warrants issued to underwriter to purchase common stock 82,500 82,500 Series A warrants to purchase common stock 2,425,605 2,449,605 Series B warrants to purchase common stock 116,580 2,449,605 Series C warrants to purchase common stock 590,415 — Series D warrants to purchase common stock 1,280,324 —

NeoForce Group, Inc. Acquisit33

NeoForce Group, Inc. Acquisition (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Schedule of Aggregate Purchase Price Consideration	The aggregate purchase price consideration was as follows: Cash consideration $ 1,000,000 Fair value of contingent consideration 153,000 Total purchase price consideration $ 1,153,000
Fair Values of Assets Acquired	The fair values of assets acquired at the transaction date are summarized below: Net tangible assets acquired $ 39,377 Customer contracts 259,730 Patents 135,890 Goodwill 718,003 Net Assets Acquired $ 1,153,000
Schedule of Unaudited Pro Forma Financial Information	The following table presents the unaudited pro forma results of Capnia, Inc. (including the operations of Neoforce) for the years ended December 31, 2014 and December 31, 2015. The unaudited pro forma financial information combines the results of operations of Capnia and NeoForce as though the companies had been combined as of the beginning of each of the fiscal periods presented. As of September 8, 2015, the date of the acquisition, the results of NFI have been combined with Capnia as a wholly-owned subsidiary. The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the consolidated results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2014 or 2015. In addition, the unaudited pro forma financial information does not attempt to project the future consolidated results of operations. December 31, December 31, 2015 2014 Pro forma total revenues $ 1,168,846 $ 987,853 Pro forma net loss $ (16,002,126 ) $ (13,307,030 ) Pro forma net loss per share — basic and diluted $ (1.70 ) $ (10.48 ) Pro forma weighted — average shares — basic and diluted 9,425,880 1,270,033

Description of Business - Addit

Description of Business - Additional Information (Detail) $ in Millions	Sep. 08, 2015USD ($)
NeoForce, Inc [Member] | NeoForce Group, Inc. [Member]
Description Of Business [Line Items]
Business acquisition upfront cash payment	$ 1

Liquidity, Financial Conditio35

Liquidity, Financial Condition and Management's Plans - Additional Information (Detail)	Jan. 08, 2016USD ($)	Oct. 15, 2015USD ($)	Oct. 12, 2015USD ($)Closings	Jul. 24, 2015USD ($)	Mar. 06, 2015USD ($)	Mar. 05, 2015USD ($)	Nov. 18, 2014USD ($)$ / sharesshares	Mar. 31, 2016USD ($)	Sep. 30, 2015USD ($)shares	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares
Liquidity And Managements Plans [Line Items]
Net loss								$ (3,189,000)		$ (11,651,000)	$ (15,908,546)	$ (13,237,616)
Accumulated deficit								(89,436,000)			(86,246,673)	(70,338,127)
Positive (deficit) in working capital								5,000,000			3,200,000
Net cash used in operating activities								(3,984,000)		(1,809,000)	(10,299,330)	(4,484,362)
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses											0	10,727,475
Proceeds from exercise of stock options								0		12,000	293,573	0
Value of common stock shares issued											293,573	9,846,552
Proceeds from issuance of Series A Convertible Preferred								5,071,000		0	4,230,150	0
Expenses related stock issuance								0		530,000	575,181	2,117,217
Series B Warrant [Member]
Liquidity And Managements Plans [Line Items]
Positive (deficit) in working capital											4,100,000
Proceeds from exercise of warrants to purchase of common stock						$ 3,800,000					3,720,713	0
Value of common stock shares issued											3,720,713
Series A Warrant [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of warrants to purchase of common stock					$ 200,000			0		156,000	156,000	$ 0
Value of common stock shares issued											$ 156,000
Private Placement Series B Warrants [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of warrants to purchase of common stock						$ 3,800,000		0		3,832,000
IPO [Member] | Series B Warrant [Member]
Liquidity And Managements Plans [Line Items]
Capital Stock, Number of Shares Per Unit | shares							1
IPO [Member] | Series A Warrant [Member]
Liquidity And Managements Plans [Line Items]
Capital Stock, Number of Shares Per Unit | shares							1
Units [Member] | IPO [Member]
Liquidity And Managements Plans [Line Items]
Number of shares issued | shares							1,650,000
Offering price per unit | $ / shares							$ 6.50
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses							$ 8,000,000
Common Stock [Member]
Liquidity And Managements Plans [Line Items]
Number of shares issued | shares											83,848	1,650,000
Value of common stock shares issued											$ 84	$ 1,650
Common Stock [Member] | Series B Warrant [Member]
Liquidity And Managements Plans [Line Items]
Number of shares issued | shares											619,512
Value of common stock shares issued											$ 619
Common Stock [Member] | Series A Warrant [Member]
Liquidity And Managements Plans [Line Items]
Number of shares issued | shares											24,000
Value of common stock shares issued											$ 24
Common Stock [Member] | IPO [Member]
Liquidity And Managements Plans [Line Items]
Capital Stock, Number of Shares Per Unit | shares							1
Series A Convertible Preferred Stock [Member]
Liquidity And Managements Plans [Line Items]
Expenses related stock issuance								$ 71,000		$ 0
Sabby Management, LLC [Member] | Series A Convertible Preferred Stock [Member]
Liquidity And Managements Plans [Line Items]
Maximum commitment under stock purchase agreement			$ 10,000,000
Number of closings | Closings			2
Proceeds from issuance of Series A Convertible Preferred	$ 5,000,000	$ 4,100,000
Expenses related stock issuance	$ 500,000	$ 400,000
Aspire Capital Fund, LLC [Member]
Liquidity And Managements Plans [Line Items]
Number of shares issued | shares									506,585
Maximum commitment under stock purchase agreement				$ 10,000,000
Agreement term				24 months
Value of common stock shares issued									$ 1,400,000

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Additional Information (Detail)	Dec. 21, 2015USD ($)	Jul. 01, 2015USD ($)	Jun. 30, 2015USD ($)shares	Jul. 31, 2015shares	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)BankSegment	Dec. 31, 2014USD ($)
Schedule Of Significant Accounting Policies [Line Items]
Number of commercial banks | Bank						2
Number of operating segments | Segment						1
Raw materials						$ 106,000
Work-in-process						398,000
Finished goods						$ 46,000
Aggregate cash payments			$ 450,000
Shares issued during period | shares			40,000	10,000
Initial payment under purchase agreement		$ 150,000
Committed payment amount			$ 100,000
Payment period one						6 months
Payment period two						12 months
Payment period three						18 months
Payments for royalties	$ 100,000
Goodwill impairment loss					$ 0	$ 0
Government grant revenue						$ 219,917	$ 0
Minimum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment						3 years
Estimated useful life					5 years	5 years
Maximum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment						5 years
Estimated useful life					12 years	12 years
Accrued Compensation and Other Current Liabilities [Member]
Schedule Of Significant Accounting Policies [Line Items]
Remaining payable amount						$ 200,000

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Intangible Assets (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amount		$ 957,620
Accumulated Amortization		(40,813)
Net Amount		$ 916,807
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years	5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years	12 years
Patents And Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Amount		$ 697,890
Accumulated Amortization		(32,155)
Net Amount		$ 665,735
Patents And Trademark [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life		5 years
Patents And Trademark [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life		12 years
Customer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Amount		$ 259,730
Accumulated Amortization		(8,658)
Net Amount		$ 251,072
Useful life		10 years

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Future Amortization Expense (Detail)	Dec. 31, 2015USD ($)
Finite-Lived Intangible Assets [Line Items]
2,016	$ 99,343
2,017	99,343
2,018	99,343
2,019	99,343
2020 and thereafter	519,435
Net Amount	916,807
Patents And Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
2,016	73,370
2,017	73,370
2,018	73,370
2,019	73,370
2020 and thereafter	372,255
Net Amount	665,735
Customer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
2,016	25,973
2,017	25,973
2,018	25,973
2,019	25,973
2020 and thereafter	147,180
Net Amount	$ 251,072

Fair Value of Financial Instr39

Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability	$ 777,000	$ 2,540,240	$ 18,296,093
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Assets
Cash and cash equivalents	3,975,000	3,803,929	7,891,888
Series A Warrant [Member]
Liabilities
Warrant liability	558,000	1,212,803	857,362
Series A Warrant [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability	558,000	1,212,803	857,362
Series B Warrant [Member]
Liabilities
Warrant liability		0	17,438,731
Series B Warrant [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability		865,000	17,438,731
Series C Warrant Liability [Member]
Liabilities
Warrant liability	219,000	462,437
Series C Warrant Liability [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability	219,000	462,437
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability	558,000	1,212,803	857,362
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Assets
Cash and cash equivalents	3,975,000	3,803,929	7,891,888
Fair Value, Inputs, Level 1 [Member] | Series A Warrant [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability	558,000	1,212,803	857,362
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability			0
Level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability	219,000	1,327,437	17,438,731
Level 3 [Member] | Series B Warrant [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability		865,000	$ 17,438,731
Level 3 [Member] | Series C Warrant Liability [Member] | Fair Value, Measurements, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities
Warrant liability	$ 219,000	$ 462,437

Fair Value of Financial Instr40

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level1 and Level 3 Financial Instruments (Detail) - USD ($)	Feb. 12, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 05, 2015
Series A Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period, in shares		2,425,605
De-recognition of Warrant liability upon exercise, in shares		(24,000)	(24,000)
Balance at the end of period, in shares		2,425,605	2,425,605
Series A Warrant [Member] | Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period		$ 1,212,803	$ 857,362
Balance at the beginning of period, in shares		2,425,605	2,449,605
Change in value of Warrant		$ (655,000)	$ 397,441
De-recognition of Warrant liability upon exercise			$ (42,000)
De-recognition of Warrant liability upon exercise, in shares			(24,000)
Balance at end of period		$ 558,000	$ 1,212,803
Balance at the end of period, in shares		2,425,605	2,425,605
Series B Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period, in shares		116,580
De-recognition of Series B Warrant liability upon expiration, in shares	(14,280)
De-recognition of Warrant liability upon exercise, in shares				(589,510)
Balance at the end of period, in shares			116,580
Series B Warrant [Member] | Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period		$ 865,000	$ 17,438,731
Balance at the beginning of period, in shares		116,580	2,449,605
Change in value of Warrant		$ (272,000)	$ 2,705,357
De-recognition of Warrant liability upon exercise			$ (3,332)
De-recognition of Series B Warrant liability upon expiration, in shares		(14,280)
De-recognition of Warrant liability upon exercise, in shares			(468)
Balance at end of period			$ 865,000
Balance at the end of period, in shares			116,580
Series B Warrant [Member] | Common stock warrant liability [Member] | Cash Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise			$ (6,747,765)
De-recognition of Warrant liability upon exercise, shares issued			619,512
De-recognition of Warrant liability upon exercise, in shares			(619,512)
Series B Warrant [Member] | Common stock warrant liability [Member] | Cashless Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise	$ (594,000)	$ (593,000)	$ (12,527,991)
De-recognition of Warrant liability upon exercise, shares issued	485,202	485,202	5,879,560
De-recognition of Warrant liability upon exercise, in shares	(102,300)	(102,300)	(1,713,045)
Series C Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Record Series C Warrant Liability		590,415	590,415
Series C Warrant Liability [Member] | Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period		$ 462,437
Balance at the beginning of period, in shares		590,415
Change in value of Warrant		$ (243,000)	$ (2,586,938)
Balance at end of period		$ 219,000	$ 462,437
Balance at the end of period, in shares		590,415	590,415
Series C Warrant Liability [Member] | Common stock warrant liability [Member] | Private Placement [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Record Series C Warrant Liability			$ 3,049,375
Record Series C Warrant Liability			590,415
Series C Warrant Liability [Member] | Common stock warrant liability [Member] | Cash Exercise [Member] | Private Placement [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, shares issued			905

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 297,595	$ 218,519
Less accumulated depreciation and amortization		(211,850)	(160,912)
Property and equipment, net	$ 121,000	85,745	57,607
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		236,366	180,238
Computer Hardware [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		52,112	27,555
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 9,117	$ 10,726

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 67,415	$ 28,516

Warrant Liabilities - Additiona

Warrant Liabilities - Additional Information (Detail) - USD ($)	Feb. 12, 2016	Mar. 06, 2015	Mar. 05, 2015	Nov. 18, 2014	Jul. 31, 2015	Mar. 31, 2016	Mar. 25, 2016	Dec. 31, 2015	Mar. 31, 2015	Feb. 12, 2016	Dec. 31, 2015	Dec. 31, 2014	Apr. 30, 2015
Class of Warrant or Right [Line Items]
Aggregate VWAP (percent)						1.00%					1.00%
Change in fair value of warrants recorded as other (income) expense						$ (1,170,000)			$ 6,174,000		$ 515,860	$ 3,941,335
Warrants cashless exercised											43,720
Issuance of shares upon cashless exercise warrants											13,407
Proceeds from issuance of common stock under tender offer											$ 1,434,194	0
Common Stock [Member]
Class of Warrant or Right [Line Items]
Issuance of shares upon cashless exercise warrants					905						5,879,560
Series C Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of common stock purchased upon issuance of warrants						590,415		590,415			590,415
Exercise price of warrants exercised			$ 6.25
Fair value of warrants outstanding								$ 500,000			$ 500,000
Change in fair value of warrants recorded as other (income) expense						$ 244,000					2,600,000
Warrants cashless exercised					905
Proceeds from issuance of common stock under tender offer					$ 5,882
Warrant liability						$ 219,000		$ 462,437			$ 462,437
Series C Warrant Liability [Member] | Common stock warrant liability [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants exercised													$ 6.25
Number of warrants						590,415		590,415			590,415
Warrants cashless exercised					905
Proceeds from issuance of common stock under tender offer					$ 5,882
Series C Warrant Liability [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Issuance of shares upon cashless exercise warrants					905
Series A Warrants to Purchase Shares of Common Stock [Member] | IPO [Member]
Class of Warrant or Right [Line Items]
Number of common stock purchased upon issuance of warrants				2,449,605		2,449,605
Exercise price of warrants exercised				$ 6.50		$ 6.50
Warrants term				5 years		5 years
Series A Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants exercised						24,000		24,000			24,000
Number of warrants						2,425,605		2,425,605			2,425,605
Fair value of warrants outstanding								$ 1,200,000			$ 1,200,000
Change in fair value of warrants recorded as other (income) expense						$ 655,000					400,000
Gross proceeds upon exercise of warrants		$ 200,000				0			156,000		156,000	0
Warrant liability						$ 558,000		$ 1,212,803			$ 1,212,803	$ 857,362
Series A Warrant [Member] | Common stock warrant liability [Member]
Class of Warrant or Right [Line Items]
Warrants exercised								24,000			24,000
Number of warrants						2,425,605		2,425,605			2,425,605	2,449,605
De-recognition of Warrant liability upon exercise											$ 42,000
Series B Warrants to Purchase Shares of Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of common stock purchased upon issuance of warrants						2,449,605		2,449,605			2,449,605
Exercise price of warrants exercised						$ 6.50		$ 6.50			$ 6.50
Warrants term											15 months
Decrease in common stock market price										$ 6.50
Series B Warrant [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants exercised			$ 6.50
Warrants exercised			589,510
Number of warrants								116,580			116,580
Change in fair value of warrants recorded as other (income) expense						$ 865,000
Warrants cashless exercised							102,300				1,713,045
De-recognition of warrant liability			$ 6,700,000
Gross proceeds upon exercise of warrants			$ 3,800,000								$ 3,720,713	$ 0
Warrant liability								$ 0			0	17,438,731
Series B Warrant [Member] | Cashless Exercise [Member]
Class of Warrant or Right [Line Items]
De-recognition of warrant liability						593,000			$ 417,000		12,527,991	$ 0
Series B Warrant [Member] | Decrease in carrying value [Member]
Class of Warrant or Right [Line Items]
Change in fair value of warrants recorded as other (income) expense						$ 271,000		$ 2,700,000			$ 16,600,000
Series B Warrant [Member] | Common stock warrant liability [Member]
Class of Warrant or Right [Line Items]
Warrants exercised								468			468
Number of warrants								116,580			116,580	2,449,605
De-recognition of Warrant liability upon exercise											$ 3,332
Series B Warrant [Member] | Common stock warrant liability [Member] | Cashless Exercise [Member]
Class of Warrant or Right [Line Items]
Warrants exercised	102,300					102,300		1,713,045		102,300	1,713,045
De-recognition of Warrant liability upon exercise, shares issued	485,202					485,202					5,879,560
De-recognition of Warrant liability upon exercise	$ 594,000					$ 593,000					$ 12,527,991
Series B Warrant [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
De-recognition of warrant liability											$ 12,500,000

Warrant Liabilities - Fair Valu

Warrant Liabilities - Fair Value of Convertible Preferred Stock Warrant Liability (Detail)	Mar. 05, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Series B Warrant [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility			90.00%	87.00%
Expected Term (years)			1 month 13 days	1 year 1 month 6 days
Expected dividend yield			0.00%	0.00%
Risk-free rate			0.65%	0.26%
Series C Warrant Liability [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility	86.00%	90.00%	90.00%
Expected Term (years)	5 years	3 years 11 months 1 day	4 years 2 months 1 day
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free rate	1.35%	1.03%	1.76%

Credit Facility - Additional In

Credit Facility - Additional Information (Detail) - USD ($)	Sep. 29, 2014	Oct. 31, 2014
Debt Disclosure [Abstract]
Line of credit amount	$ 100,000
Line of credit, fixed interest rate per annum	6.00%
Line of credit, repayment term	2 years
Amount of line of credit		$ 100,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Mar. 01, 2016ft²	Sep. 30, 2015	Sep. 08, 2015USD ($)	Jul. 01, 2015USD ($)ft²	Feb. 02, 2015USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)ft²	Dec. 31, 2014USD ($)
Loss Contingencies [Line Items]
Non-cancelable operating lease agreement term				4 years
Area of real estate property (in sqft) | ft²				8,171
Future minimum commitment under non-cancelable operating lease | $				$ 23,300	$ 22,000			$ 2,413,733
Additional area of office space for headquarters facility | ft²	5,265			5,265
Lessee Leasing Arrangements, Operating Leases, Increases to Monthly Payments, Term					2 years
Rent expense | $						$ 184,000	$ 62,000	$ 375,000	$ 230,000
Ivyland, Pennsylvania [Member]
Loss Contingencies [Line Items]
Area of real estate property (in sqft) | ft²								2,100
NeoForce Group, Inc. [Member] | NeoForce, Inc [Member]
Loss Contingencies [Line Items]
Royalty payment period		36 months	36 months			36 months
Fair value of royalty | $			$ 153,000			$ 172,000		$ 153,000

Commitments and Contingencies47

Commitments and Contingencies - Minimum Rental Payments (Detail) - USD ($)	Dec. 31, 2015	Jul. 01, 2015	Feb. 02, 2015
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 698,945
2,017	750,118
2,018	629,923
2,019	334,747
Total	$ 2,413,733	$ 23,300	$ 22,000

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail)	Mar. 31, 2016$ / sharesshares	Jan. 08, 2016$ / sharesshares	Dec. 31, 2015Vote$ / sharesshares	Dec. 31, 2014$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized | shares	100,000,000		100,000,000	100,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.001		$ 0.001	$ 0.001
Number of votes per share | Vote			1
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, shares authorized | shares	40,000		40,000	40,000
Convertible preferred stock, shares issued | shares	8,335	10,000	4,555	0
Convertible preferred stock, stated value (in dollars per share) | $ / shares	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock, stated value (in dollars per share) | $ / shares	$ 1,000	$ 1,000	$ 1,000

Stockholders' Equity (Deficit49

Stockholders' Equity (Deficit) - Additional Information (Detail) - USD ($)	Mar. 16, 2016	Jan. 27, 2016	Jan. 05, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Jan. 08, 2016	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				$ 136,000	$ 401,000	$ 942,369	$ 345,435
Number of options granted						955,713	926,384
Weighted average grant date fair value per option granted (in dollars per share)						$ 1.66	$ 1.03
Future stock-based compensation for unvested employee options granted and outstanding				$ 1,800,000		$ 1,917,245
Future stock-based compensation, requisite service period				3 years 2 months 12 days
Stock options outstanding, intrinsic value						$ 67,165
Aggregate VWAP (percent)				1.00%		1.00%
Warrants cashless exercised						43,720
Issuance of shares upon cashless exercise warrants						13,407
Warrants Issued in 2009 to Purchase Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants				9,259		9,259
Exercise price of warrants (in dollars per share)				$ 21.60		$ 21.60
Warrants term				10 years		10 years
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant				139,839		139,839
Annual increases in the number of shares available for issuance, percentage of outstanding common stock				1.00%		1.00%
Annual increases in the number of shares available for issuance, number of shares				279,680		279,680
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ownership interest of voting rights of all classes of stock (percent)				10.00%		10.00%
NSO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value				85.00%		85.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years		4 years
Income tax benefit from stock compensation expense				$ 0	$ 0	$ 0	$ 0
Number of options granted				538,500		955,713	926,384
Future stock-based compensation, requisite service period						2 years 6 months
Number of shares available for grant				128,066		6,149	606,061		124,824
Annual increases in the number of shares available for issuance, number of shares				560,717		270,764
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value				110.00%		110.00%
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option				10 years		10 years
ISOs [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option				5 years		5 years
Series A Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible preferred stock, shares authorized				40,000		40,000	40,000
Convertible preferred stock, shares issued				8,335		4,555	0	10,000
Convertible preferred stock, par value (in dollars per share)				$ 0.001		$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock, stated value (in dollars per share)				$ 1,000		$ 1,000		$ 1,000
Number of shares converted	1,665	1,665	1,665	1,665
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued upon conversion	900,000	900,000	900,000	900,000
Series D Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants				2,810,811		1,280,324
Exercise price of warrants (in dollars per share)				$ 2.46		$ 2.46
Warrants term				5 years		5 years
Aggregate VWAP (percent)				1.00%		1.00%
Warrants to Purchase Stock [Member] | 2010 and 2012 Convertible Promissory Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants				480,147		480,147
Exercise price of warrants (in dollars per share)				$ 4.87		$ 4.87
Warrants term				10 years		10 years
Underwriter [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants				82,500		82,500
Exercise price of warrants (in dollars per share)				$ 7.14		$ 7.14
Warrants term				10 years		10 years
Sabby Management, LLC [Member] | Series A Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible preferred stock, shares issued								5,445

Stockholders' Equity (Deficit50

Stockholders' Equity (Deficit) - Summary of Stock Based Compensation Expense (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	$ 136,000	$ 401,000	$ 942,369	$ 345,435
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	33,000	50,000	148,948	64,020
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	(31,000)	20,000	62,533	8,335
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	$ 134,000	$ 331,000	$ 730,888	$ 273,080

Stockholders' Equity (Deficit51

Stockholders' Equity (Deficit) - Stock Option Assumptions (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life			6 years 1 month 6 days
Dividend rate	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 years	5 years 6 months		5 years 9 months 18 days
Risk-free interest rate	1.50%	1.50%	1.60%	1.60%
Volatility	66.00%	57.00%	56.00%	43.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 years 1 month 6 days	6 years 1 month 6 days		6 years 1 month 6 days
Risk-free interest rate	1.70%	1.60%	1.70%	1.80%
Volatility	67.00%	68.00%	66.00%	59.00%

Stockholders' Equity (Deficit52

Stockholders' Equity (Deficit) - Summary of Stock Option Transactions (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Options Outstanding
Options granted (in shares)		955,713	926,384
Weighted Average Remaining Contractual Term
Options vested at end of period (in years)		7 years 5 months 19 days	7 years 5 months 16 days
Options vested and expected to vest at end of period (in years)		8 years 9 months	8 years 8 months 1 day
Stock Options [Member]
Shares Available for Grant
Beginning balance (in shares)	6,149	606,061	124,824
Additional shares authorized (in shares)	560,717	270,764
Options granted (in shares)	(538,500)	(955,713)	(926,384)
Options canceled/forfeited (in shares)	99,700	85,037	93,979
Ending balance (in shares)	128,066	6,149	606,061
Number of Options Outstanding
Beginning balance (in shares)	1,858,839	1,072,011	239,606
Options granted (in shares)	538,500	955,713	926,384
Options exercised (in shares)	0	(83,848)
Options canceled/forfeited (in shares)	(99,700)	(85,037)	(93,979)
Ending balance (in shares)	2,297,639	1,858,839	1,072,011
Options vested at end of period (in shares)		922,927	578,889
Options vested and expected to vest at end of period (in shares)		1,858,839	1,072,011
Weighted-Average Exercise Price per Share
Beginning balance (in dollars per share)	$ 4.82	$ 6.34	$ 3.36
Options granted (in dollars per share)	1.59	3.08	7.15
Options exercised (in dollars per share)	0	3.50
Options canceled/forfeited (in dollars per share)	2.33	5.03	6.75
Ending balance (in dollars per share)	$ 4.09	4.82	6.34
Options vested at end of period (in dollars per share)		5.06	5.58
Options vested and expected to vest at end of period (in dollars per share)		$ 4.82	$ 6.34
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term (in years)	8 years 9 months 7 days	8 years 9 months	8 years 8 months 1 day
Stock Options [Member] | 2014 Plan [Member]
Shares Available for Grant
Additional shares authorized (in shares)			1,437,165
Stock Options [Member] | Closed 2010 Plan [Member]
Shares Available for Grant
Options Available, Expired (in shares)			(123,523)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Expense by Applying Statutory U.S. Federal Income Tax Rate to Income Before Income Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax on the loss before income tax expense computed at the federal statutory rate of 34%	$ (5,408,551)	$ (4,717,063)
State tax (benefit) at statutory rate, net of federal benefit	(928,107)	(13,020)
Change in Valuation Allowance	4,199,154	1,578,347
Change in research and development credits	(60,991)	316,311
Change in fair value of warrants	1,493,215	2,960,766
Other	705,280	(125,341)
Income tax expense	$ 0	$ 0
Effective income tax rate	0.00%	0.00%
Federal statutory rate percentage	34.00%	34.00%

Income Taxes - Significant Comp

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Non-Current Deferred Tax Assets:
Reserves and accruals	$ 287,850	$ 71,953
Net Operating Loss Carryforwards	26,174,912	22,125,807
Research and development credits	1,381,296	1,345,833
Intangible Assets		46,784
Intangible Assets	(74,113)
Fixed Assets	9,080
Fixed Assets		(10,505)
Total Non-Current Deferred Tax Assets	27,779,025	23,579,872
Valuation Allowance	(27,779,025)	(23,579,872)
Net Deferred Tax Assets	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Increase in the valuation allowance	$ 4,199,154
Unrecognized tax benefit offset by change in valuation allowance	691,697
Unrecognized tax benefits impacting effective tax rate	0	$ 0
U.S. Federal Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards	67,263,865
U.S. Federal Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Income Tax Contingency [Line Items]
Tax credit carryforwards	1,328,082
State Tax Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards	56,650,176
State Tax Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Income Tax Contingency [Line Items]
Tax credit carryforwards	$ 977,574

Income Taxes - Summary of Gross

Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 673,247	$ 0
Increase related to prior year tax positions	0	628,383
Decreases related to prior year tax positions	(13,207)	0
Increase related to Current year tax positions	31,657	44,864
Decreases related to current year tax positions	0	0
Ending Balance	$ 691,697	$ 673,247

Net loss per share - Schedule o

Net loss per share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Underwriter [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	82,500	82,500	82,500	82,500
Series A Warrants to Purchase Shares of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	2,425,605	2,425,605	2,425,605	2,449,605
Series B Warrants to Purchase Shares of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	0	1,778,275	116,580	2,449,605
Series C Warrant to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	590,415	589,510	590,415	0
Series D Warrant To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	2,810,812	0	1,280,324	0
Warrants Issued to 2010/2012 Convertible Note Holders to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	480,147	480,147	480,147	523,867
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	2,297,639	1,458,964	1,858,839	1,072,011
Warrants Issued in 2009 to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	9,259	9,259	9,259	9,259
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	4,505,405	0	2,462,162	0

NeoForce Group, Inc. Acquisit58

NeoForce Group, Inc. Acquisition - Additional Information (Detail) - NeoForce Group, Inc. [Member] - USD ($)	Sep. 30, 2015	Sep. 08, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Revenue of acquiree				$ 279,000
Net income of acquiree				76,000
NeoForce, Inc [Member]
Business Acquisition [Line Items]
Business acquisition upfront cash payment		$ 1,000,000
Royalty payment period	36 months	36 months	36 months
Royalty payable				8,372
Fair value of royalty		$ 153,000	$ 172,000	$ 153,000
Fair value inputs, discount rate		20.00%	20.00%
Amortization					$ 53,000

NeoForce Group, Inc. Acquisit59

NeoForce Group, Inc. Acquisition - Schedule of Aggregate Purchase Price Consideration (Detail) - NeoForce Group, Inc. [Member] - NeoForce, Inc [Member]	Sep. 08, 2015USD ($)
Business Acquisition [Line Items]
Cash consideration	$ 1,000,000
Fair value of contingent consideration	153,000
Total purchase price consideration	$ 1,153,000

NeoForce Group, Inc. Acquisit60

NeoForce Group, Inc. Acquisition - Fair Values of Assets Acquired (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Sep. 08, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Other intangible assets, net	$ 718,000	$ 718,003		$ 0
NeoForce Group, Inc. [Member] | NeoForce, Inc [Member]
Business Acquisition [Line Items]
Net tangible assets acquired			$ 39,377
Other intangible assets, net			718,003
Net Assets Acquired			1,153,000
NeoForce Group, Inc. [Member] | NeoForce, Inc [Member] | Customer Contracts [Member]
Business Acquisition [Line Items]
Net intangible assets acquired			259,730
NeoForce Group, Inc. [Member] | NeoForce, Inc [Member] | Patents [Member]
Business Acquisition [Line Items]
Net intangible assets acquired			$ 135,890

NeoForce Group, Inc. Acquisit61

NeoForce Group, Inc. Acquisition - Schedule of Unaudited Pro Forma Financial Information (Detail) - NeoForce Group, Inc. [Member] - NeoForce, Inc [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Pro forma total revenues	$ 1,168,846	$ 987,853
Pro forma net loss	$ (16,002,126)	$ (13,307,030)
Pro forma net loss per share - basic and diluted (in dollars per share)	$ (1.70)	$ (10.48)
Pro forma weighted-average shares-basic and diluted (shares)	9,425,880	1,270,033

Subsequent Events (Detail)

Subsequent Events (Detail)	Mar. 16, 2016shares	Feb. 12, 2016shares	Jan. 27, 2016shares	Jan. 08, 2016USD ($)$ / sharesshares	Jan. 05, 2016Fundshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 25, 2016shares	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Apr. 26, 2016pharmacy_chainLocation
Subsequent Event [Line Items]
Number of funds | Fund					2
Stock issuance costs | $						$ 0		$ 530,000	$ 575,181	$ 2,117,217
Warrants cashless exercised									43,720
Common stock, shares issued						15,403,111	485,202		14,017,909	6,769,106
Series D Warrants [Member]
Subsequent Event [Line Items]
Proceeds from warrants | $				$ 5,000,000
Stock issuance costs | $				$ 500,000
Number of warrants						2,810,811			1,280,324
Series B Warrant [Member]
Subsequent Event [Line Items]
Number of warrants									116,580
Warrants cashless exercised							102,300		1,713,045
Number of warrants expired in period		14,280
Sabby Management, LLC [Member] | Series D Warrants [Member]
Subsequent Event [Line Items]
Number of warrants issued				1,471,622
Maxim Group Llc [Member] | Series D Warrants [Member]
Subsequent Event [Line Items]
Number of warrants issued				58,865
Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares converted	1,665		1,665		1,665	1,665
Convertible preferred stock, shares issued				10,000		8,335			4,555	0
Convertible preferred stock, stated value (in dollars per share) | $ / shares				$ 1,000		$ 1,000			$ 1,000
Convertible preferred stock, par value (in dollars per share) | $ / shares				$ 0.001		$ 0.001			$ 0.001	$ 0.001
Stock issuance costs | $						$ 71,000		$ 0
Series A Convertible Preferred Stock [Member] | Sabby Management, LLC [Member]
Subsequent Event [Line Items]
Convertible preferred stock, shares issued				5,445
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued upon conversion	900,000		900,000		900,000	900,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of pharmacy chains | pharmacy_chain											2
Number of retail locations | Location											150

Summary of Significant Accoun63

Summary of Significant Accounting Policies - Inventory (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Raw materials	$ 290,000	$ 106,000
Work-in-process	267,000	399,000
Finished goods	96,000	46,000
Total inventory	$ 653,000	$ 551,008	$ 109,336

Fair Value of Financial Instr64

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	Jan. 13, 2016	Sep. 08, 2015	Mar. 31, 2016	Dec. 31, 2015
Redwood City, California [Member] | Level 3 [Member] | Sublease of Excess Space [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value inputs, discount rate	20.00%
NeoForce, Inc [Member] | NeoForce Group, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of royalty		$ 153,000	$ 172,000	$ 153,000
Fair value inputs, discount rate		20.00%	20.00%